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ABSTRACT 
 
Secretion of toxins into host cells is an important component of microbial 
pathogenesis.  In order to gain access to the host cell cytosol, toxins must cross the 
plasma membrane, traverse the membrane of endocytic vesicles, or cross the membrane 
of organelles.  The process cytolysin-mediated translocation (CMT) in Streptococcus 
pyogenes uses the pore-forming protein streptolysin O (SLO) to translocate the S. 
pyogenes NAD+-glycohydrolase (SPN) effector into the cytosol of eukaryotic host cells.  
Although, the fundamentals of this protein translocation process are established the 
details of the mechanism remain elusive. 
The current studies illustrate that the translocation process is more complex than 
initially projected.  It was thought that the effector protein, SPN, entered the host cell 
cytosol through the lumen of the translocator, SLO.  In this thesis, mutational analysis 
demonstrates that SPN translocation into the host cell does not require SLO pore 
formation.  Furthermore, the SLO pore-forming mutant and wild type strains use an 
indistinguishable pathway to translocate SPN.  While the pore-forming mutant can 
translocate SPN, the cytotoxic affects of CMT occur only when SLO forms pores and 
translocates SPN.  These studies illustrate that SLO pore formation can occur 
independently of SPN secretion and that there is a synergistic effect between these two 
SLO activities.  Further studies using pharmacological inhibitors to probe the 
involvement of the host cell during CMT indicate that clathrin-dependent endocytosis 
does not play a role.  The carboxyl-terminus of SLO makes contact with the host cell 
membrane through an area denoted as Domain 4.  Mutational studies indicate that 
 iii 
 
expression of Domain 4 from the related pore-forming protein, perfringolysin O (PFO), is 
insufficient for CMT.  Moreover, CMT is unaffected by extraction of cholesterol to levels 
that block membrane binding by the cholesterol-dependent PFO protein.  Although 
cholesterol is unnecessary, mutations that interrupt cholesterol binding by SLO indicate 
the sterol does increase the efficiency of CMT.  Furthermore, a loop region within 
Domain 4 is important and provides SLO with its specificity in CMT.  Taken together, 
even though SLO binds to cholesterol, there might be an additional membrane receptor 
necessary for CMT.  In total, the research described in this thesis furthers the knowledge 
of the CMT mechanism and provides opportunities for future investigation into the role 
of CMT in infections. 
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Classification of Streptococcus 
 
Bacteria classified within the genus Streptococcus are members of the phylum 
Firmicutes and the lactic acid group of bacteria.  Streptococci are facultative anaerobic 
Gram-positive bacteria that are non-motile, have a spherical shape, and form chains (11).  
Streptococci are categorized according to their intrinsic hemolytic property.  Alpha-
hemolytic streptococci do not lyse red blood cells, but appear greenish in color on blood 
agar plates due to the reduction of iron in hemoglobin.  Gamma-hemolytic streptococci 
do not have the ability to rupture or affect red blood cells.  Beta-hemolytic streptococci 
are able to completely lyse red blood cells to produce a zone of clearance on blood agar 
plates generally because of the secreted toxin Streptolysin S.  The beta-hemolytic 
streptococci are further distinguished by the presence of specific carbohydrates on their 
bacterial surface, which are identified using Lancefield serotyping (52). 
Streptococcus pyogenes is a beta-hemolytic and Lancefield Group-A bacterium.  
Additional classification of Group A streptococci occurs based on the type of M protein 
adhesin present on the surface of the bacterium (Figure 1).  These adhesins have a central 
and conserved C-terminal domain anchored to the S. pyogenes cell wall via an LPXTG 
motif (15, 24, 63).  The N-terminal region of M protein, described as the hyper-variable 
domain, is the source of the diversity in this family of proteins used to classify the M type 
(15, 24, 63).  Currently, there are over 180 types of M protein known, with M1 and M12 
being the most prevalent in the United States (94, 98). 
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Figure 1.  The structure of the S. pyogenes M protein adhesin.  The carboxyl terminus of the 
adhesin is attached to the bacterial cell membrane.  Each M type adhesin is distinctive because 
the amino terminus of the protein contains a variable region, which is encoded by many different 
sequences.  Adapted from Ref. (24).  
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Diseases and the prevalence of S. pyogenes 
 
S. pyogenes is a bacterial pathogen that can infect both soft and deeper tissues 
resulting in non-invasive and invasive diseases, respectively.  Diseases that occur due to 
an infection with S. pyogenes can be suppurative (pus forming) or non-suppurative 
sequelae.  The suppurative infections can arise from both non-invasive and invasive 
diseases (17).  The ability of S. pyogenes to infect many organs allows it to cause a wide 
array of ailments (Figure 2). 
 
 
Figure 2.  The pathogenesis of S. pyogenes infections in humans.  The various organs that S. 
pyogenes can infect and the resulting diseases are shown.  Adapted from Ref. (75). 
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Clinical manifestations of an S. pyogenes infection range from mild and self-
limiting to those that are severe and life threatening.  Soft tissue infection sites including 
the mucous membranes, tonsils, and skin are suppurative infections that lead to non-
invasive diseases such as pharyngitis (strep throat) and impetigo (17).  These diseases are 
typically treated using antibiotics such as penicillin and cephalosporins, though penicillin 
is the preferred option. 
Deep tissue S. pyogenes infections can cause severe and invasive diseases which 
include necrotizing fasciitis, streptococcal toxic shock syndrome, sepsis, and meningitis 
(17).  These deep tissue infections can be suppurative infections that do not respond to 
penicillin and can ultimately lead to death.  Post-infectious sequelae, for instance acute 
rheumatic fever and glomerulonephritis, develop as a result of a previous S. pyogenes 
infection that was not adequately treated (18).  The onset of acute rheumatic fever is 
generally accompanied by autoimmune diseases such as rheumatic heart disease, 
rheumatic arthritis, or the neurological disease Sydenham chorea (18).  
Glomerulonephritis is characterized by inflammation of blood vessels in the kidney and 
eventual renal failure (18). 
While S. pyogenes can cause post-infectious and invasive disease, the archetypal 
infection manifests as a non-invasive disease.  Annually, it is estimated that there are over 
700 million cases of S. pyogenes infections worldwide that cause superficial diseases 
(e.g., pharyngitis) (12).  According to the Centers for Disease Control and Prevention, in 
the United States there are greater than 10 million infections that cause mild diseases like 
pharyngitis and the majority of these infections occur in school-age children (1).  
However, non-invasive disease can occur in all age groups, including adults who live in 
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close quarters such as dormitories and military barracks (17).  In comparison to the non-
invasive disease statistics, the numbers of severe disease worldwide and in the U.S. are 
far fewer.  Globally there are around 18 million cases of invasive and post-infectious 
disease with approximately 2 million new cases each year (12).  In the United States, 
there are approximately 9,000 to 11,500 S. pyogenes infections that lead to invasive 
disease and ultimately 1,000 to 1,800 individuals die as a result (1).  Even though S. 
pyogenes has the ability to infect multiple organs, in total, these statistics suggest that the 
development of severe disease is rare.  Thus, the typical S. pyogenes infection does not 
end with death, which potentially allows the bacteria to infect other individuals in the 
population. 
There is evidence indicating that the nasopharynx serves as the location of the S. 
pyogenes reservoir (72).  S. pyogenes is an exclusively human pathogen and there are 
potentially two reservoir populations.  Individuals (e.g., children) treated with antibiotics 
for pharyngitis and tonsillitis, but who continue to develop recurrent S. pyogenes 
infections, might be one possible reservoir population (73, 74).  Alternatively, a second 
reservoir population may consist of individuals who are asymptomatically colonized (62).  
An anomalous fact is that as many as 30% of individuals who receive penicillin do not 
successfully clear a S. pyogenes infection (89).  Additionally, the only known antibiotic 
resistance is towards macrolides (erythromycin) and not penicillin (6, 26).  Some of the 
individuals that do not respond to antibiotics have active recurrent infections, while 
others are culture positive without any symptoms. 
The current model for the formation of the S. pyogenes reservoirs suggests that 
bacteria can invade host epithelial cells and thereby resist antibiotics and host defenses 
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until conditions improve.  Previous work shows that several strains of S. pyogenes, 
collected from infected individuals, are able to adhere and invade epithelial cells grown 
in vitro culture, in medium containing antibiotics for at least 4 days (56, 71, 89).  
Additionally, removal of the antibiotics initiates the release of S. pyogenes from the 
epithelial cells and allows extracellular bacteria growth to resume (71).  There are also 
reports that suggest the genes necessary for encoding specific adhesins are present in S. 
pyogenes strains isolated from individuals with recurrent infections and from 
asymptomatic individuals (62, 64).  Histological sections of S. pyogenes infected 
epithelial cells show adherent and intracellular bacteria (72).  Electron microscopy 
images of tissue sections, from recurrently infected and asymptomatic individuals, 
indicate that S. pyogenes is present in the epithelial cells of the tonsils and pharynx (72, 
73).  A recent report states that the S. pyogenes genome is present in tissue sections from 
individuals with recurrent tonsillitis (95).  However, attempts to culture S. pyogenes from 
the infected tissues were unsuccessful even though several non-related bacterial species 
did grow from the same samples (95).  Taken together, this data supports the notion that 
S. pyogenes is present in tissue samples, but the inability to culture the bacteria suggests 
the organisms might not be viable.  There is an abundant amount of data indicating that S. 
pyogenes can enter cells to evade clearance and antibiotic treatment, however, further 
work is necessary to assess the capacity of these bacteria to reestablish infections. 
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Adhesins on the surface of S. pyogenes 
  
 The ability of S. pyogenes to infect various types of tissue and cause disease 
depends on its effective adherence to human cells.  There are approximately twenty 
different adhesins identified for S. pyogenes (15).  The expression of these various 
adhesins differs by strain and by the environmental conditions in which the bacterium 
grows (15).  Three major adhesins present on the surface of S. pyogenes that facilitate 
binding are the M protein, fibronectin binding protein (Protein F or Sfb), and lipoteichoic 
acid. 
M protein, which is encoded by the emm gene, is secreted and covalently 
anchored to the cell membrane via an LPXTG motif present in the carboxyl terminus 
(24).  Two M protein polypeptides then assemble on the surface of S. pyogenes to form a 
fibrous alpha helical coiled-coiled protein (Figure 1).  Each M protein has a carboxyl 
terminus that contains a conserved C repeat domain and an amino terminus that contains 
highly variable sequence (24).  The conserved C repeat domain is necessary for M 
protein to bind to CD46, a membrane cofactor protein present on keratinocytes (skin 
cells) and lung epithelial cells, as demonstrated by the inability of S. pyogenes strains 
lacking M protein or lacking the C repeat domain to bind to keratinocytes (69, 70, 82).  
Additionally, Lactococcus lactis binds CD46 on the surface of lung epithelial cells when 
M protein is heterologously expressed (82).  Previous reports show that M protein can 
also bind fibrinogen, fucose-glycoproteins, and sialic acid modified proteins (15).  The 
amino terminus of M protein is also known to confer antiphagocytic properties to S. 
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pyogenes (24).  M protein is therefore a versatile adhesin that protects S. pyogenes and 
permits the bacterium to bind to various cell types. 
There are many adhesins on the surface of S. pyogenes dedicated to binding the 
extracellular matrix components such as fibronectin, vitronectin, collagen, integrins, 
laminin, and heparin sulfate (15).  Fibronectin, a large extracellular matrix glycoprotein 
that binds to integrin receptors present in the membrane of human cells, is widely used as 
a receptor for S. pyogenes adhesions(15).  Furthermore, fibronectin binding proteins are 
important for adherence to many different cell types (15).  At least five different 
fibronectin binding proteins in S. pyogenes are covalently attached to the bacterial cell 
wall via an LPXTG motif and contain a binding domain that is made of repeating units 
(Figure 3) (88).  These repeating units significantly increase the ability of the five 
proteins to bind to fibronectin (88).  Protein F is the first member of this protein family 
identified in S. pyogenes; this protein is able to bind soluble and insoluble fibronectin (16, 
35).  In addition to the five proteins with the fibronectin binding domain, S. pyogenes 
expresses a number of other adhesins that can bind to fibronectin including lipoteichoic 
acid.  A two-step binding method might be important for S. pyogenes adherence, with 
lipoteichoic acid making the initial contact with the host cell membrane followed by 
another adhesion binding to its receptor (15).  The diverse number of adhesins anchored 
to the S. pyogenes cell wall provides the bacteria the access necessary to adhere to and 
infect various human cells. 
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Figure 3.  S. pyogenes adhesins that contain fibronectin binding domains.  Fibronectin 
binding proteins are anchored to the cell wall.  These proteins contain a minimum of three 
fibronectin binding domains at the carboxyl terminus.  Adapted from Ref. (88). 
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Toxins and Enzymes Secreted from S. pyogenes 
 
 During the course of an infection, S. pyogenes secretes over 40 toxic proteins and 
enzymes that are important for survival within the host (23, 60).  The streptococcal 
pyrogenic exotoxins, also known as superantigens, are a large family of secreted proteins 
that are extremely perilous (5, 7).  These proteins uncontrollably stimulate T cells to 
induce a massive immune response and lead to the disease state known as streptococcal 
toxic shock syndrome.  Other secreted proteins help S. pyogenes evade the immune 
system.  The serine protease streptococcal C5a peptidase, anchored to the bacterial cell 
wall, can cleave the human protein C5a to prevent immune cell recruitment, allowing the 
bacteria to continue proliferating (11).  Enzymes such as hyaluronidase and DNase 
secreted by S. pyogenes may help the bacteria gather nutrients and spread the infection (7, 
11).  Several other enzymes play a key role in the capability of the S. pyogenes infection 
to spread through the tissue (Figure 4).  Streptokinase disintegrates clots by converting 
plasminogen to plasmin and glucuronidase can degrade glycosaminoglycans found in the 
extracellular matrix.  The secreted cysteine protease SpeB cleaves both host and bacterial 
proteins.  SpeB release of streptococcal proteins from the bacterial surface and 
degradation of streptococcal proteins present in the extracellular milieu may assist S. 
pyogenes evasion of the immune system (13). 
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Streptokinase 
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Figure 4.  Toxins and enzymes secreted by Streptococcus pyogenes.  Over 40 proteins are 
secreted during an S. pyogenes infection to support nutrient acquisition, bacterial replication, and 
immune evasion.  Listed here are examples of those proteins (5, 7, 11). 
 
 
Streptolysin O and S are two hemolysins that possess an ability to lyse and harm 
structures in the body including erythrocytes, polymorphonuclear leucocytes, organelles, 
and tissues.  The hemolysis observed on blood agar plates is mostly due to the secretion 
of Streptolysin S (SLS).  SLS is a small-modified peptide that is non-immunogenic, 
oxygen-stable, and associates with the bacterial cell wall.  Delivery and toxicity of the 
SLS is optimal when S. pyogenes is in contact with the target (11, 66).  Additionally, the 
production of SLS allows S. pyogenes to circumvent the host immune response and 
prevent the recruitment of neutrophils (53).  Streptolysin O forms oligomeric pores in the 
membrane of mammalian cells.  The following section will provide further information 
about this hemolytic toxin.   
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Cholesterol-dependent Cytolysins 
 
 Gram-positive pathogenic bacteria secrete many pore-forming toxins including 
the cholesterol-dependent cytolysins (CDC).  Over 20 species, including the genera 
Streptococcus, Clostridium, Listeria, Bacillus, and Arcanobacterium, secrete these pore-
forming proteins, which have 40-70% amino acid sequence similarity (91).  The CDC’s 
are large oligomers consisting of 35 to 50 cytolysin monomers that produce beta-barrel 
pores ranging in size from 25 to 30 nm in diameter (38).  The resolved three-dimensional 
structure of three members of the CDC family – perfringolysin O from Clostridium 
perfringens, intermedilysin from Streptococcus intermedius, and anthrolysin O from 
Bacillus anthracis – demonstrate that each soluble cytolysin folds into four discontinuous 
domains (8, 77, 85) (Figure 5).     
 
 
 
Figure 5.  Perfringolysin O, intermedilysin, and anthrolysin O monomer structures.  The 
ribbon diagrams illustrate the structure of three members of the CDC protein family.  Four 
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discontinuous domains are visible in all three cytolysin protein monomers.  Domain 4 makes 
contact with the host cell membrane and domain 3 contains two sets of three α-helices that 
become transmembrane-β-hairpins, which insert into the membrane.  Adapted from Refs.  (8, 
100). 
 
 
The structural similarity between the three cytolysins suggests that the other 
members of the CDC protein family likely have a similar arrangement and pore forming 
mechanism (Figure 5).  Extensive research conducted with perfringolysin O (PFO) 
provides details regarding the mechanism of pore formation (Figure 6).  Water soluble 
cytolysin monomers secreted from the bacteria initially bind to the surface of the host cell 
via domain 4 of the protein (100).  As the monomers bind, only the tip of domain 4 
inserts into the host cell membrane and each monomer is perpendicular to the membrane 
(37, 79, 81).  In each cytolysin monomer, domain 3 has two sets of three short α-helices.  
The primary domain 4 binding event triggers movement of a short β strand in domain 3 
of each monomer and disrupts hydrogen bond interactions between the short β strand and 
a short α-helix (Figure 7) (81).  This movement in domain 3 reveals the interface through 
which the cytolysin monomers can interact (81).  Once the short β strand in domain 3 
moves, the two sets of the three short α-helices undergo a conformation change and 
become two transmembrane-β-hairpins (strands β1 – β4, Figure 7) (81, 90, 91).  The β1 
strand of the β-hairpin from one cytolysin monomer interacts with the β4 strand of the β-
hairpin from the adjacent monomer (Figure 7) (81).   
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Figure 6.  Mechanism of cytolysin pore formation.  The structural domains of the cytolysin are 
numbered.  Stage I:  Each soluble cytolysin monomer binds to the membrane via the carboxyl 
terminus (domain 4).  Stage II:  A series of conformational changes throughout the structure of 
each cytolysin initiates oligomerization to form the multimeric prepore complex on the surface of 
the membrane.  Stage III:  Additional structural movements within each monomer of the prepore 
complex leads to the vertical collapse of domain 1 and domain 2, which permits the insertion of 
the domain 3 transmembrane-β-hairpins into the membrane to form a large β-barrel pore.  
Adapted from (38). 
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Figure 7.  Formation of the cytolysin transmembrane-β-hairpins.  The structure of domain 3 
at each stage of pore formation is shown.  Stage I:  Two sets of three α-helices are present in each 
cytolysin monomer.  Stage II:  Once the cytolysins bind to the membrane, a short β strand (β5) in 
domain 3 shifts to reveal the monomer-monomer interaction surface, which will initiate formation 
of the prepore complex.  Stage III:  In each cytolysin monomer, the two sets of three short α-
helices unravel to form two transmembrane-β-hairpins, which will insert into the membrane to 
form a pore.  The β1 strand of from a cytolysin monomer interacts with the β4 strand of the 
adjacent cytolysin monomer.  Adapted from (38). 
 
 
As the monomers form hydrogen bonds between each other on the surface of the 
membrane an oligomeric structure, known as the prepore complex, forms (Figure 6) (37, 
40-42, 92).  The prepore complex sits on the surface of the membrane (19).  Formation of 
the prepore complex is the rate-limiting step of cytolysin pore formation and the two β-
hairpins of each monomer can insert into the membrane once assembly of the complex is 
complete (42, 43).  Insertion of the domain 3 transmembrane-β-hairpins involves 
movement of domain 1 closer to the membrane, bending of the β sheets in domain 2, and 
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a 40 Å vertical collapse of the prepore complex into the membrane, which results in the 
formation of a large transmembrane β-barrel (Figure 6) (19, 20, 80). 
The interaction between domain 4 and the membrane requires further 
investigation because the receptor for many of the cytolysins is unknown.  Recent studies 
reveal that domain 4 of each cytolysin binds to cholesterol and possibly a separate 
receptor.  Pore formation by PFO, streptolysin O and intermedilysin (ILY) requires the 
presence of cholesterol in the membrane (31).  However, in the case of streptolysin O and 
ILY, binding to host cell membranes occurs independently of cholesterol because 
membrane binding and pore formation are separate activities (31).   
One member of the CDC family, ILY, only lyses human cells as a result of its 
domain 4 sequence and this specificity is transferable to other cytolysins (77).  The 
specificity that ILY displays towards human cells is due to its receptor CD59, which is a 
protein that prevents complement deposition on human cell membranes (32).  Even 
though ILY binds CD59, three loops present in domain 4 of the protein must bind to 
cholesterol for the ILY prepore complex to insert into the membrane to form a pore (21, 
51, 96).  Cholesterol, the PFO receptor, is necessary and sufficient to trigger 
oligomerization and formation of pores by the cytolysin (25, 39, 65).  Mutations in the 
domain 4 loops of PFO prevent it from binding to cholesterol (97).  Additionally, PFO 
requires only two residues in loop 1 of domain 4 to bind membrane cholesterol (21).  
While the majority of the research on cytolysins have focused on PFO, there is evidence 
that streptolysin O forms pores using a similar mechanism (40).  Although streptolysin O 
requires cholesterol to complete pore formation, the receptor for this cytolysin is 
unknown. 
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The CDC family member expressed by S. pyogenes, streptolysin O (SLO), is a 
571 amino acid protein that has a Sec-dependent signal sequence at its amino terminus, 
similar to most other CDC’s.  However, unlike most other members of the CDC protein 
family, SLO has additional sequence at its amino terminus, known as the N-terminal 
extension (48, 58).  Within this N-terminal extension, there is a cleavage site for the S. 
pyogenes cysteine protease SpeB, which releases 47 amino acids from SLO (76).  Both 
the uncleaved and cleaved forms of SLO are detectable in the overnight S. pyogenes 
culture supernatants and both retain hemolytic activity (18, 76). 
Studies conducted with deletion strains demonstrate that cytolysins secreted by 
the pathogenic Gram-positive bacteria have an important role during an infection.  The 
CDC family of proteins can form pores in the plasma membrane of host cells, including 
immune cells, in the membranes of organelles, and in the membranes of endocytic 
vesicles (22, 33, 44, 46, 57, 78, 87).  However, while pore formation is an important 
function of these proteins, there is evidence that cytolysins have alternative functions 
independent of forming pores (4, 34, 93).  Recent work with S. pyogenes demonstrates 
that the SLO pore is not required for translocation of the secreted NAD+-glycohydrolase 
and that there is specificity in the translocation activity of SLO (55). 
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Gram-negative type three secretion system 
 
Trafficking of bacterial toxins into host cells is essential for the virulence of 
nearly all pathogenic bacteria (3, 67).  The transported toxins can interfere with the host 
intracellular signaling pathways to alter the potential response of the host immune system 
and to allow the bacteria to proliferate.  Many Gram-negative bacteria use specialized 
secretion systems, such as the Type III secretion system (T3SS), to direct bacterial toxins 
into the host cell cytosol (30, 36).  The T3SS specifically delivers bacterial proteins, 
known as effectors, into the host cell cytosol using a needle complex called the 
injectisome (Figure 8) (27, 61).  After the needle complex makes contact with the host 
cell membrane, the first effectors released by the T3SS are proteins that form a pore in 
the host membrane (61).  The needle complex then translocates other effector proteins via 
the protected channel from the bacterial cytosol, across the bacterial membranes, through 
the pore, and into the host cell cytosol (27). 
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Figure 8.  The Gram-negative type three secretion system complex.  A series of proteins are 
secreted by the bacterium to form the needle complex, which traverses the two bacterial 
membranes and the periplasm.  The needle complex secretes the proteins that make up the pore 
(translocase complex) in the host cell membrane.  Once this pore forms, chaperones bring other 
effector proteins to the T3SS and an ATPase complex supplies the energy for the translocation 
process.  Adapted from Ref. (27). 
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Cytolysin-mediated translocation 
 
The process of cytolysin-mediated translocation (CMT) is the first description of 
a Gram-positive bacterium, S. pyogenes, possibly using a system analogous to the T3SS, 
to target a secreted protein into the host cell cytosol (Figure 9) (54).   This process uses 
the cytolysin SLO to translocate the S. pyogenes NAD+-glycohydrolase (SPN) into the 
cytosol of the cell host causing cytotoxicity (10, 54).   
 
 
 
Figure 9.  Original model of cytolysin-mediated translocation in S. pyogenes.  The pore 
forming protein (SLO) translocates the effector protein (SPN) across the host cell membrane.  
Adapted from Ref. (54). 
 
 
In the S. pyogenes genome, spn and slo are in an operon along with a third gene 
named ifs (Figure 10).  Upstream of spn is nusG, which encodes a transcription 
antitermination factor (14).  Downstream of slo are a series of predicted small open 
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reading frames and metB, which encodes a putative cystathionine beta-lyase involved in 
amino acid, sulfur, and nitrogen metabolism (2).  A promoter present in front of spn 
likely controls the expression of the three genes in the operon, however very little is 
known about the regulation of these genes (50).  Other reports suggest that there is also a 
weak promoter in front of slo within the ifs sequence (47, 48, 86).  A secretory signal 
present at the amino terminus of SPN and SLO permits secretion of the two proteins from 
the bacterial cytosol and across the cell wall using the Sec-dependent secretion system 
(84).  Following secretion from S. pyogenes, SLO directs SPN into the host cell. 
 
 
 
Figure 10.  The spn operon and the surrounding genes in S. pyogenes.  Three proteins 
required for CMT are encoded in a single operon.  A promoter (represented by an arrow) 
upstream of spn is thought to control the expression of spn, ifs, and slo.  The flanking genes nusG 
and metB genes are not likely involved in CMT.  The three predicated open reading frames 
downstream of slo do not have any predicted gene assignments and there is no information about 
the function of the putative protein products.  One gene (SpyM3-0131) is conserved in all 
sequenced strains of S. pyogenes. 
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Prior to initiating the studies described in Chapters 2, 3 and 4, the following 
general characteristics of SPN translocation were known.  In the absence of SLO, 
translocation of SPN into the host cell cytosol does not occur (10, 54).  Compared to a 
wild type S. pyogenes infection, an intraperitoneal infection with a SPN- strain produces 
attenuation in disease resulting in a reduction in the mortality of mice (9).  Similarly, 
deletion of either slo or spn leads to a decrease in host cell cytotoxicity suggesting CMT 
is important for pathogenesis (10, 54).  In addition, S. pyogenes strains that are unable to 
adhere to the host cell due to the absence of M protein also are unable to translocate SPN, 
suggesting CMT is a contact dependent process (54).  A simple model of CMT predicts 
that SPN passively diffuses into the host cell through the 30 nm diameter SLO pore.  
However, the observation that streptococci translocate approximately 70% of the total 
SPN secreted into eukaryotic cells in vitro indicates that CMT is more complex (10, 54).  
Other data demonstrates that a mixed infection with isogenic slo- and spn- mutants is 
unable to restore SPN translocation (54).  This result indicates that 1) SPN does not 
diffuse into the host cell cytosol through the SLO pore, 2) one bacterium must coordinate 
the expression and secretion of both proteins, and 3) the localized concentration of SPN 
and SLO at the membrane is important for successful CMT.  In total, these results lead to 
the development of a CMT model in which SPN enters the host cell cytosol through the 
SLO pore (Figure 9).  The high levels of SPN present in the cytosol suggest that SPN 
translocation does not occur via diffusion, but involves a mechanism that permits directed 
protein transport into the host cytosol.  In addition, since bacterial adherence is necessary 
for SPN translocation and the SLO pore is thought to be required, a revised model was 
formed that suggested CMT was similar to the Gram-negative T3SS. 
 24 
Although it is acknowledged that CMT requires SLO to translocate SPN, the 
mechanism of this process is unknown.  Unlike other members of the family, SLO has an 
N-terminal extension, which does not share sequence homology with other cytolysins 
(48, 58).  In addition to the SpeB cleavage site, the N-terminal extension appears to 
encode a putative protein-protein interaction region (58).  Removal of 18 residues that 
encode the putative interaction region did not affect CMT suggesting that those residues 
did not make any crucial contacts with another protein (58).  However, deletion of the 
entire N-terminal extension abrogates the ability of SLO to translocate SPN into the 
cytosol of eukaryotic cells, but does not affect pore formation (58).  PFO is unable to 
translocate SPN when expressed from a S. pyogenes SLO- strain, but retains the ability to 
form pores (58).  The expression of a protein chimera molecule, grafting the N-terminal 
extension of SLO onto full length PFO, does not result in SPN translocation although the 
chimera is also capable of forming pores (58).  Hence, even though the N-terminal 
extension of SLO is necessary, it is not sufficient to make a related cytolysin CMT-
competent.  Moreover, pore formation alone is not sufficient to allow CMT to proceed.  
Overall, these results indicate cytolysin pore formation and translocation can be 
uncoupled.  The inability of PFO to complement the function of SLO suggests that pores 
may not be necessary for CMT.  This data also indicates that CMT is not a passive 
diffusion process, but is an active process that requires SLO to translocate the majority of 
SPN into the host cell cytosol.   
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NAD+-glycohydrolase (SPN) effector protein and the specificity of CMT 
 
Currently, SPN is the only described effector protein translocated by CMT.  As an 
NAD+-glycohydrolase, SPN cleaves β-NAD+ to form two products: nicotinamide and 
ADP-ribose (Figure 11) (28).  Although previous studies suggested that SPN also 
contains cyclase and ADP-ribosyl transferase activities (45, 99), a recent report 
definitively demonstrates that SPN is a strict NAD+-glycohydrolase lacking the two other 
enzymatic activities once thought to be associated with the protein (28). 
 
 
 
Figure 11.  The NAD+-glycohydrolase enzymatic reaction.  SPN is a glycohydrolase that 
cleaves β-NAD+ to form nicotinamide and ADP ribose.  Adapted from Ref. (28). 
 
 
Several studies show that CMT involves the translocation of SPN into the host 
cell cytosol, however, it is not clear if there is a CMT signal sequence present in SPN or 
if other secreted S. pyogenes proteins also enter the host cell via CMT.  Recent work in 
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our lab illustrates that CMT is not a universal process in that it can discriminate between 
substrates: SPN and mitogenic factor (another S. pyogenes secreted toxin) (29).  
Moreover, any deletions in the primary SPN sequence are intolerable and inhibit CMT 
(29).  This sequence stringency is not required for the NAD+-glycohydrolase activity, as 
deletion of the first 190 residues composing the amino terminus uncoupled translocation 
of SPN from its enzymatic activity (29).  However, deletions made from the carboxyl-
terminus of SPN prevent both enzymatic activity and translocation (29).  Protein 
chimeras expressing increasing amounts of the amino-terminus of SPN in conjunction 
with the full sequence of mitogenic factor did not permit translocation of this alternative 
substrate (29).  The placement of mitogenic factor in the center of the SPN primary 
sequence hinders translocation of the protein chimera, but does not affect the NAD+-
glycohydrolase activity of SPN (29).  Mitogenic factor can enter the host cell cytosol 
only when placed at the end of the entire primary sequence of SPN (29).  This protein 
chimera is both CMT-competent and NAD+-glycohydrolase positive.   
Overall, these studies indicate that CMT can effectively discriminate between 
secreted streptococcal proteins.  In addition, the NAD+-glycohydrolase activity of SPN 
resides in the carboxyl terminus and deletions in the sequence of SPN uncouple 
translocation from the enzyme activity.  The amino terminus of SPN may be important 
for the polar translocation that occurs during CMT suggesting that the SPN mutants 
described in the study have an altered structure that prevents them from interacting with 
SLO properly during CMT.  Hence, SPN plays an active role in CMT and does not 
passively diffuse through the SLO pore.   
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Inhibitor of NAD+-glycohydrolase activity in S. pyogenes 
Two potential spn alleles naturally exist within the population of S. pyogenes 
strains (68, 83).  One allele is glycohydrolase positive and the operon encodes ifs, which 
produces the immunity factor for SPN (IFS) (59).  The second allele is glycohydrolase 
negative and the operon contains many nonsense mutations in ifs, which no longer 
produces a functional protein.  The IFS protein competes with β-NAD+ and inhibits the 
glycohydrolase activity of SPN (49, 59).  Without IFS, streptococcal cells are susceptible 
to the toxic effects of glycohydrolase positive SPN suggesting that some amount of 
protein may fold in the bacterial cytosol (59). 
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Chapter II 
 
Streptococcus pyogenes cytolysin-mediated translocation 
does not require streptolysin O pore formation 
 
 48 
SUMMARY 
 
Bacterial toxin injection into the host cell is required for the virulence of 
numerous pathogenic bacteria.  Cytolysin-mediated translocation (CMT) of 
Streptococcus pyogenes uses streptolysin O (SLO) to translocate the S. pyogenes 
nicotinamide adenine dinucleotide-glycohydrolase (SPN) into the host cell cytosol, 
resulting in the death of the host cell.  Although SLO is a pore-forming protein, previous 
studies have shown that pore formation alone is not sufficient for CMT to occur.  Thus, 
the role and requirement of the SLO pore remains unclear.  In this study, we constructed 
various S. pyogenes strains expressing altered forms of SLO to assess the importance of 
pore formation.  We observed that SLO mutants that are unable to form pores retain the 
ability to translocate SPN.  In addition, SPN translocation occurs after inhibition of actin 
polymerization, suggesting that CMT occurs independently of clathrin-mediated 
endocytosis.  Moreover, despite the ability of mutants to translocate SPN, their cytotoxic 
effect requires SLO pore formation. 
 
Modified from Magassa et al. (2010) EMBO Reports 
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INTRODUCTION 
 
Secretion and trafficking of bacterial toxins into host cells is essential for the 
virulence of nearly all pathogenic bacteria (1, 24).  Cytolysin-mediated translocation 
(CMT) in Streptococcus pyogenes — an organism that causes a wide range of 
complications, including mild diseases (such as pharyngitis and impetigo), life-
threatening invasive diseases (such as necrotizing fasciitis) and post-infectious sequelae 
(such as glomerulonephritis and rheumatic fever) — uses the multimeric pore-forming 
cytolysin streptolysin O (SLO) to translocate the S. pyogenes nicotinamide adenine 
dinucleotide (NAD+)-glycohydrolase (SPN) across the host cell membrane (4, 20).  S. 
pyogenes NAD+-glycohydrolase cleaves β-NAD+ to produce nicotinamide and ADP-
ribose, and it can also perform cyclase and ADP ribosyl transferase reactions (18, 31).  
Although the mechanism of translocation is unknown, deletion of either slo or spn leads 
to both decreased cytotoxicity and virulence suggesting CMT is important for 
pathogenesis (3, 4, 20).  
A simple model predicts that translocation of SPN into the host cell occurs by 
diffusion through the 30 nm SLO pore.  However, several observations suggest that the 
process is more complex, including that co-infection with isogenic slo and spn mutants is 
unable to restore CMT (20), that the related cytolysin perfringolysin O (PFO) cannot 
complement an SLO- mutant (23), and that CMT can discriminate between SPN and 
other streptococcal proteins (10).  Furthermore, deletion of specific amino acid residues 
in SPN and SLO renders each of them incompetent for CMT, without altering their other 
functions (NADase activity and pore formation, respectively) (10, 23).  Altogether, the 
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data indicate that both SPN and SLO play an active role in CMT and that SPN does not 
passively diffuse through the SLO pore.  
The ability to uncouple SLO pore formation from CMT indicates that the 
presence of pores is not sufficient for SPN translocation.  This raises the question as to 
whether pore formation is even necessary for CMT.  The SLO and PFO proteins are 
members of the cholesterol-dependent cytolysin (CDC) family, found in several 
pathogenic Gram-positive bacterial species.  The three-dimensional structure of PFO and 
several other CDCs reveals that these proteins have an analogous domain structure and 
use a similar mechanism to form pores (33).  The bacterium secretes soluble cytolysin 
monomers and pore formation begins when the monomers bind to the host cell membrane 
through domain 4 of the protein.  The monomers then associate to form an oligomeric 
structure, known as the prepore complex, which is bound to the cell surface but does not 
insert into the host cell membrane.  Finally, conformational changes in domain 3 of each 
monomer convert a pair of three alpha-helical bundles into two transmembrane-β-
hairpins.  This transformation leads to insertion of the prepore complex into the 
membrane to form a functional pore with a lumen ranging from 30 nm to 50 nm in 
diameter (33).  The mechanism of pore formation has been studied extensively in PFO.  
Specific mutations in domain 3 lock the protein at different stages of pore formation (33).  
In this study, we generated an analogous set of locked SLO mutants and used these to 
assess the necessity of the SLO pore in CMT. 
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RESULTS 
 
SLO mutants locked at various stages of oligomerization:  On the basis of studies using 
PFO, the substitution of two conserved adjacent glycine residues located in domain 3 of 
SLO (monomer-locked, Table 1), with two valine residues, was predicted to inhibit the 
interactions that lead to oligomerization of subunits (33).  The substitution of a conserved 
domain 3 tyrosine residue with alanine (prepore-locked, Table 1) was predicted to allow 
monomers to bind and form an oligomeric structure on the host cell membrane but 
prevent insertion of the pore (33).  To verify oligomerization phenotypes, the mutant 
SLO proteins were expressed with a 6X histidine linker at their carboxy-termini and 
purified from Escherichia coli (Figure 1). 
 
 
Figure 1:  Purified SLO protein variants visualized on a gel stained with Coomassie 
brilliant blue.  The (A) WT SLO, (B) prepore-locked SLO, and (C) monomer-locked SLO 
proteins were expressed with a C-terminal 6X histidine tag, purified using metal ion affinity 
chromatography, subjected to SDS-PAGE using a 10% gel, and stained with Coomassie brilliant 
blue for visualization.  The image shown is representative of data obtained from three 
independent experiments.  SLO, streptolysin O; wt, wild type. 
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Table 1.  Bacterial stains used in this study. 
Strains Relevant genotype/Description/Comments a Reference 
JRS4 wild type/WT (28) 
SLO6 sloΔ113-447/SLO- 
SLO deficient mutant 
(27) 
SPN1 spnΔ177-319/SPN- 
SPN deficient mutant 
(20) 
NGM1 sloY255A/prepore-locked 
Expresses prepore-locked SLO 
This study 
NGM2 sloG398V/G399V/monomer-locked 
Expresses monomer-locked SLO 
This study 
SLOΔ37-102 sloΔ37-102/SLOΔNT 
Expresses SLO lacking an N-terminal translocation domain 
(23) 
NGM3 sloΔ37-102,Y255A/PreporeΔNT 
Expresses prepore-locked SLO lacking an N-terminal translocation domain 
This study 
a Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the 
mutant alleles. 
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The soluble purified proteins were incubated in the presence of a cholesterol and 
phospholipid mixture mimicking biological membranes and examined by negative-stain 
electron microscopy.  As expected, WT SLO formed oligomeric ring structures in the 
presence of the membrane constituents (Figure 3A).  The prepore-locked SLO was able 
to form ring structures similar to WT, but these structures were not observed when the 
monomer-locked protein was incubated with the lipid mixture (Figure 3A).  To confirm 
functional phenotypes, Western blot analysis showed that the WT, prepore-locked and 
monomer-locked SLO proteins were stable and expressed at equivalent levels (Figure 2). 
 
 
 
 
Figure 2:  WT, prepore, and monomer-locked SLO proteins are stable and expressed.  Cell-
free overnight S. pyogenes culture supernatant from the (A)  WT, (B)  prepore-locked, and (C)  
monomer-locked strains were precipitated on ice with 10% trichloroacetate, subjected to 
centrifugation, washed with acetone, and analyzed by a Western blot using anti-SLO antiserum to 
visualize the various SLO proteins (23).  The image shown is representative of data obtained from 
three independent experiments.  SLO, streptolysin O; wt, wild type. 
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As expected, treatment of A549 lung carcinoma cells with cell-free overnight-culture 
supernatants from a strain expressing WT SLO resulted in the release of lactate 
dehydrogenase (LDH).  By contrast, treatment with supernatants from strains expressing 
prepore- and monomer-locked SLO promoted minimal LDH release, which was 
indistinguishable from that produced by an SLO- mutant (Figure 3B).  Furthermore, 
unlike wild-type SLO, prepore- and monomer-locked SLO could not promote detectable 
lysis of erythrocytes at either neutral or acidic pH (Figure 3B).  These data confirm that 
the mutant SLO proteins are not capable of forming a functional pore. 
 
SLO mutants are associated with cell membranes:  The process of oligomerization and 
pore formation requires cytolysins to bind to the host cell membrane.  After an infection 
with the WT and mutant strains, A549 cells were fractionated with Triton X-100.  
Western blot analysis illustrated that WT SLO localized to the Triton X-100 insoluble 
membrane fraction (Figure 3C).  Prepore-locked and monomer-locked SLO proteins also 
localized to the A549 cell membrane fraction and were present in amounts similar to WT 
SLO (Figure 3C).  None of these proteins were detected in the Triton X-100 soluble 
fraction (not shown).  These results indicate that even though mutant SLO proteins were 
unable to form pores, both bound membrane as efficiently as WT SLO. 
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Figure 3.  Prepore- and monomer-locked mutants of streptolysin O localize to host cell 
membranes but cannot form pores.  (A) Negative-stain electron microscopy was used to 
visualize the ability of the purified SLO mutant proteins to oligomerize in the presence of 
cholesterol and phospholipids.  The images shown are representative of data from three 
independent experiments.  Scale bars, 50 nm.  (B) The pore-forming ability of the indicated SLO 
proteins was assessed by hemolytic activity at pH 7.0 and 6.5 (titers shown) and by the release of 
LDH from A549 cells (compared with the total LDH released from lysed cells – control, shown 
above).  A ‘0’ indicates that no lysis was detected with undiluted supernatant.  Data represent 
mean±s.e.m. values derived from three independent experiments.  (C) After infection for 3.75 
hrs, A549 cells were subjected to fractionation with Triton X-100.  A Western blot analysis of the 
insoluble fraction compared with a precipitate prepared from an overnight culture supernatant 
(control) is shown.  The image shown is representative of data obtained from three independent 
experiments.  LDH, lactate dehydrogenase; SLO, streptolysin O; wt, wild type. 
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Pore formation is not required for CMT:  To assess the requirement for pore formation 
in CMT, the prepore and monomer-locked strains were used to infect A549 cells.  The 
efficiency of SPN translocation was evaluated according to the percentage of the total 
SPN expressed, which was translocated into the A549 cell cytosol.  Consistent with the 
requirement for SLO, the wild-type strain was CMT-competent with most (typically more 
than 70%) of the total SPN expressed in the A549 cell cytosolic fraction, whereas the 
SLO- mutant was markedly deficient for CMT (typically less than 10%; Figure 4).  By 
contrast, even though prepore-locked SLO was unable to form pores, the mutant strain 
translocated SPN at levels indistinguishable from WT (Figure 4).  Although reduced from 
that of the prepore-locked strain, the monomer-locked SLO strain was also CMT 
competent and translocated SPN at levels significantly higher than the SLO- mutant 
(Figure 4; P<0.005).  These data indicate that pore formation was not required for CMT 
and that, although not essential, SLO oligomerization did improve the efficiency of CMT. 
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Figure 4.  CMT is not dependent on pore formation but is enhanced by oligomerization.  
The ability of the SLO pore-forming mutants (Table 1) to translocate SPN into the A549 cell was 
analyzed.  The bars show the percentage of the total SPN expressed that was translocated into the 
A549 cytosolic fraction, after a 3.75 h infection.  An ‘*’ indicates that CMT is significantly lower 
than wild type (P<0.0001) and ‘**’ indicates CMT is at levels higher than SLO- (P<0.005).  The 
data represent the mean±s.e.m. values derived from at least three independent experiments.  
CMT, cytolysin-mediated translocation; SLO, streptolysin O; SPN, Streptococcus pyogenes 
nicotinamide adenine dinucleotide-glycohydrolase; wt, wild type. 
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Mutants use a similar CMT pathway:  To ascertain whether the same SPN translocation 
pathway was used by the WT and prepore-locked strains, we examined the importance of 
the SLO amino terminus and sensitivity to cytochalasin D.  A previous study 
demonstrated that deletion of 66 residues at the N-terminus of SLO (SLO∆NT) prevented 
SPN translocation, but did not affect the ability of the mutant protein to form pores (23).  
In addition, inhibitors of actin polymerization known to block the host cell clathrin-
mediated endocytic pathway (Figure 5) did not prevent WT SLO from conducting CMT 
(4, 20).   
0
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Figure 5: Albumin uptake by A549 cells is inhibited in the presence of cytochalasin D. A549 
cells were untreated or treated with 2 μg/mL cytochalasin D at 37ºC or 4ºC.  The cells were then 
incubated with Alexa-Fluor 594 albumin for 1 hr and uptake measured by counting the total 
number of cells stained with the fluorophore.  The data represent the mean and the standard 
deviation of the mean derived from at least three independent experiments.  CytoD, cytochalasin 
D. 
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A strain was constructed that expressed a prepore-locked SLO that also lacked the N-
terminal translocation domain (prepore∆NT, Table 1).  As expected, this strain lost the 
ability to lyse erythrocytes, a characteristic of both WT and the strain expressing SLO 
with only the N-terminal deletion (SLO∆NT, Table 1, Figure 6A).  However, prepore∆NT 
also lost the competence of WT for CMT (P<0.0001) and was as defective as SLO∆NT 
(Figure 6A), demonstrating that the ability of the prepore-locked strain to conduct CMT 
is also dependent on the N-terminal domain.  Furthermore, similar to WT, the presence of 
cytochalasin D did not alter the ability of the prepore-locked strain to conduct CMT 
(Figure 6B).  Previous studies indicate that at least one CDC has the ability to bind to and 
signal via the Toll-like receptor 4 (TLR4) (21, 30).  However, a specific TLR4 antagonist 
(HTA125, Figure 6D) had no capacity to inhibit CMT by WT or the prepore-locked 
strain (Figure 6C).  These data show that the CMT pathway promoted by prepore-locked 
SLO is indistinguishable from that of WT SLO. 
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Figure 6.  The CMT pathway used by the prepore-locked and WT SLO are 
indistinguishable.  (A) CMT efficiencies of the indicated strains (top) and hemolytic titers 
(bottom) were assessed and presented as described for Figure 4.  CMT efficiency by the indicated 
strains (Table 1) after treatment of A549 cells with (B) cytochalasin D or (C) the TLR4 
antagonist HTA125 are shown.  Data represent mean±s.e.m. values and an ‘*’ indicates that CMT 
is significantly lower than WT (P<0.0001).  (D)  LPS activation of TLR4 is inhibited in the 
presence of the monoclonal antibody HTA125.  A549 cells were untreated, treated with 10 μg/mL 
of the isotype control IgG2a, or treated with 10 μg/mL of the monoclonal anti-TLR4 antibody 
HTA125.  The cells were then incubated with LPS for 24 hours and TLR4 stimulation was 
measured by the presence of IL-6 in the supernatant.  CMT, cytolysin mediated translocation; 
SLO, streptolysin O; SPN, Streptococcus pyogenes nicotinamide adenine dinucleotide-
glycohydrolase; TLR4, Toll-like receptor 4; IL-6, interleukin-6; LPS, lipopolysaccharide; wt, 
wild type. 
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Pore formation is required for cytotoxicity:  To determine whether cytotoxicity requires 
both SLO pore formation and SPN translocation, A549 cells were infected with the WT 
and mutant strains and membrane integrity assessed by staining with the membrane-
impermeable fluorescent probe ethidium homodimer (EthH-1) (20).  After 5 hrs, most of 
WT-infected A549 could not exclude EthH-1 indicating that their membranes were 
compromised (Figure 7).  By contrast, infection with the prepore-locked and monomer-
locked strains resulted in a more than 90% reduction in numbers of EthH-1-staining cells 
compared with WT (P<0.0001).  These reduced levels were similar to infection by SLO- 
and SPN- strains (Figure 7).  This reduction in cytotoxicity by the locked mutants 
occurred despite the presence of cytosolic SPN.  Although reduced from WT, co-
infection by SPN- (which produces SLO) and prepore-locked strains produced a 
significantly higher number of cells with damaged membranes compared to SLO- mutant 
alone (Fig. 4, P<0.0001).  These data indicate that although SPN translocation occurred 
in the absence of an SLO pore, the synergistic SLO/SPN cytotoxic response requires both 
the translocation and pore-forming activities of SLO. 
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Figure 7.  Cytotoxicity requires both SLO pore formation and SPN translocation.  The 
percentage of A549 cells with cytosolic EthH-1 staining after infection by the indicated strains is 
shown (Table 1).  An ‘*’ indicates that EthH-1 staining of A549 cells is significantly lower than 
wild type (P<0.0001) and ‘**’ indicates that EthH-1 staining is at levels higher than SLO- 
(P<0.0001).  Data represent mean±s.e.m. values derived from at least three independent 
experiments.  EthH-1, ethidium homodimer 1; SLO, streptolysin O; SPN, Streptococcus pyogenes 
nicotinamide adenine dinucleotide-glycohydrolase. 
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DISCUSSION 
 
Cytolysin-mediated translocation has been compared previously with specialized 
secretion systems, such as the Gram-negative type III secretion system, which inject 
effector proteins into the host cell cytosol (8).  It has been established that SPN is 
translocated through CMT and that SLO is necessary for this process.  According to an 
early model of CMT, SLO actively translocated SPN into the host cell cytosol through 
the lumen of its pore.  However, data presented here show that the SLO pore is not 
required for SPN translocation. 
Although these data do not reveal the pathway for SPN uptake, they do contribute 
to a growing appreciation that CDCs possess alternative activities that do not rely on pore 
formation.  For example, after binding to the membrane, listeriolysin O and pneumolysin 
initiate signaling events that result in histone dephosphorylation and deacetylation in the 
absence of pores, causing alterations in the host cell gene expression profile (14).  
Similarly, pneumolysin can stimulate cytokine secretion and caspase I activation 
independently of pore formation (2, 29).  Overall, these reports suggest that cytolysins 
with dual functionality might be prevalent and that pore formation might be a secondary 
activity in certain circumstances.  
Pore formation was necessary for cytotoxicity, but the mechanism underlying this 
synergistic effect is also unclear.  However, it is known that cells have the capacity to 
heal SLO pores (15, 34) and it is possible that SPN could interfere with this process.  
Cellular wound healing is also a localized process (15), which could explain why a mixed 
infection only partly restored cytotoxicity, as the site of SPN delivery and that of pore 
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formation would not be coupled efficiently.  However, it cannot be ruled out that the 
prepore-locked protein exhibited a dominant-negative effect through the formation of 
mixed oligomers that resulted in an overall reduction in pore formation.  
Given that pore formation is not required for CMT, data presented here suggest a 
more active role for the host cell.  Streptolysin O is known to bind to cholesterol through 
domain 4, thus implicating clathrin-independent endocytosis through lipid rafts (19, 22), 
followed by the release of SPN into the host cell cytosol as a possible CMT mechanism.  
Several CDCs, including listeriolysin O and PFO, have been shown to localize to 
cholesterol-enriched domains of membranes (9, 25), suggesting that SLO also might be 
present in similar membrane domains.  A recent report argues against this pathway and 
indicates that the initial binding of PFO is preferentially to free cholesterol at the 
membrane surface, rather than to cholesterol associated with lipid rafts  (7). 
It is also becoming apparent that CDCs can exhibit marked differences in how 
they bind to the membrane, ranging from those that recognize a specific protein to those, 
such as PFO, that bind exclusively to cholesterol (33). Interestingly, SLO demonstrates 
much less dependence on binding to cholesterol than does PFO (11), suggesting that SLO 
might recognize an additional membrane receptor. Thus, a rigorous biophysical 
investigation of how SLO binds to the membrane, including determination of whether 
CMT is affected by ‘reprogramming’ binding specificity by swapping domain 4 of SLO 
with that of other CDCs, probably holds the key to understanding the CMT uptake 
pathway. 
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MATERIAL AND METHODS 
 
Table 2.  Primers used in this study. 
Name Sequence/Description a 
NM301p 
NM302p 
AAAAAAAACCAAGCGACCG
AAAAAATGATT
AATCAATG 
CGGTCG
Mutagenesis primers for NGM1 
CTTGTGTTCTG  
NM32p 
NM33p 
AGCTCATTTACAGCTGTCGTTTTAGTAGTAGATGCTGCAGAGCACAATAAGGTGG 
CCACCTTATTGTGCTCTGCAGCATCTACTACTAAAACGACAGCTGTAAATGAGCT  
Mutagenesis primers for NGM2 
MAM29 
MAM30 
AAAAAAAAACTCTAGA
AAAAAAAAAAC
GATTCAGCATTAGCAGTAACAAGG 
TCTAGA
 Mutagenesis primers for NGM3 
GAAGAGCGAAGAAGATCACACTGAAG 
NM300p 
MAM6 
AAAAAAAAACTCGAG
CTGCTCGC
GAATGATAAAAAGGTATGAAGG 
ATCGAT
Primers to amplify slo from pABG5 for insertion into pJRS233 
CTACTTATAAGTAATCGAACCA  
NM46p 
NM66p 
AAAAAAACCATGG
AAAAAA
AATCGAACAAACAAAACACTGCTAGTACAGAAACC 
TCTAGA
Primers to amplify slo for insertion into pBAD/gIII 
CTAATGATGATGATGATGATGGCCGGCACCCTTATAAGTAATCGAACCATATGG  
a Sequence is shown 5’ to 3’.  Engineered restriction endonuclease sites are underlined. 
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Bacterial strains:  Molecular cloning experiments used Escherichia coli TOP10 cells.  
The studies with Streptococcus pyogenes utilized the M serotype 6 strain JRS4 (28).  
Routine culture of S. pyogenes and E. coli was conducted as previously described (23).  
Where appropriate, chloramphenicol or erythromycin was added to media at final 
concentrations of 15 μg/ml for E. coli and 3 μg/ml for S. pyogenes or 750 μg/ml for E. 
coli and 1 μg/ml for S. pyogenes, respectively.  
 
Manipulation and computational analyses of DNA:  Transformation of E. coli and 
plasmid DNA isolation were performed as previously described (5).  Construction of S. 
pyogenes mutants was conducted using standard methods (23).  Briefly, each slo mutant 
allele (sloY255A, sloG398V/G399V, sloΔ37-102,Y255A) was generated using a pMAM1.4 template 
(23) with the primers listed in Table 2 and the product inserted into the vector pABG5 
containing a chloramphenicol cassette (13).  The mutant alleles were amplified from 
pABG5 using the primers in Table 2 and inserted into pJRS233, a temperature-sensitive 
vector containing an erythromycin resistance cassette (26).  The WT slo allele in JRS4 
was substituted with the mutant allele using allelic replacement as previously described 
(17).  Restriction endonucleases, ligases, and polymerases were used according to 
manufacturer’s recommendations.  The fidelity of all DNA sequences created by PCR 
was validated by DNA sequencing analyses performed by a commercial vendor 
(SeqWright; Galveston, TX). 
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Purification of SLO:  Mutant and WT slo alleles were expressed in E. coli by using the 
pBAD/gIII vector (cat.#V45001, Invitrogen) and were amplified by using the primers 
listed in Table 2.  The bacteria were grown in Luria Bertani medium containing 100 
μg/mL of ampicillin and 0.02% arabinose added to induce expression of recombinant 
proteins.  The cells were pelleted, resuspended in buffer (20 mM Tris HCl pH 8.0 with 
20% sucrose), incubated on ice with lysozyme (15 mg/mL) in the presence of EDTA 
(100 mM), and harvested by centrifugation.  Expression constructs contained a C-
terminal 6X histidine tag and were expressed and purified by metal ion affinity 
chromatography using commercial matrix (cat.#635503, Clontech).  Purity was assessed 
by SDS–PAGE and staining with Coomassie brilliant blue R250 (Figure 1). 
 
Analysis of SLO oligomerization:  Purified SLO proteins (0.65 μg) were incubated for 1 
hr at 25°C in the presence of lipid mixture (0.5 mg/ml) containing about 50 mol% 
cholesterol and about 50 mol% 1,2 dioleoyl-sn-glycero-3-phosphocholine (cat.#850375, 
Avanti) as described previously (6).  Samples were allowed to absorb onto 
formvar/carbon-coated copper grids for 10 min.  Grids were washed in dH2O and stained 
with 1% aqueous uranyl acetate (Ted Pella, Redding, CA, USA) for 1 min.  Excess liquid 
was wicked off gently and grids were allowed to air-dry.  Samples were viewed on a 
JEOL 1200EX transmission electron microscope (JEOL USA, Peabody, MA) at an 
accelerating voltage of 80 kV. 
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A549 cell fractionation:  After infection, A549 cells were lysed using Tris-buffered 
saline containing 1% Triton X-100 (cat.#T8787, Sigma), collected by scraping, and 
fractions were prepared by ultracentrifugation as described previously (20).  Triton-X-
100-insoluble and -soluble fractions were subjected to sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) using an 8% gel and analyzed by 
Western blot analysis using SLO (23). 
 
Analysis of CMT:  The S. pyogenes strains used in this study are listed in Table I and 
were constructed by standard methods as detailed.  Analysis of CMT by using A549 cells 
was conducted as described previously (10, 23).  Where indicated, cytochalasin D (2 
μg/mL, cat.#C2618, Sigma) or the TLR4 antagonist HTA125 (10 μg/mL, cat.#HM2068, 
Cell Sciences) were added to media for 30 and 60 min., respectively, before infection by 
streptococcal strains.  This cytochalasin D treatment has been shown to inhibit 
endocytosis (Figure 5), but not CMT (20).  This HTA125 treatment inhibited 
lipopolysaccharide-induced secretion of interleukin-6 (Figure 6D), similar to that 
observed elsewhere (35).  Data presented represent the mean and the standard error of the 
mean derived from at least three independent experiments. 
 
Analysis of cytotoxicity:  The integrity of A549 cell membranes after infection was 
assessed by the ability to exclude the membrane-impermeable fluorescent probe EthH-1 
by using a commercial reagent (Live/Dead, cat.#L3224, Invitrogen) as described 
previously (20). The ability to lyse erythrocytes and to promote LDH release was 
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analyzed as described previously (20, 23, 27).  The data presented represent the mean and 
the standard error of the mean derived from at least three independent experiments. 
 
Cytochalasin D treatment of A549 cells:  The technique employed to assess the affect 
of cytochalasin D on A549 cells was modified from Tagawa et al as described: A549 
cells were seeded into 12-well tissue culture plates and grown in the presence of cell 
culture medium (DMEM, 50 mM HEPES, 8 mM L-glutamine, and 10% fetal bovine 
serum).  Confluent A549 cells were washed with and kept in the presence of serum-free 
cell culture medium.  The cells were then treated for 30 minutes with cytochalasin D 
(cat.#C2618, Sigma) at a final concentration of 2 μg/mL at 37ºC or 4ºC.  Following the 
pretreatment, the cells were incubated with Alexa-Fluor 594 albumin (cat.#A13101, 
Invitrogen) for 1 hr at 37ºC or 4ºC.  Samples were visualized on a Leica DMIRE2 
inverted microscope.  Uptake was measured by counting the total number of cells stained 
with the fluorophore.  The data represent the mean and the standard deviation of the mean 
derived from at least three independent experiments.  Cytochalasin D inhibits the uptake 
of albumin by A549 cells similar to prior observations (16, 32) (Figure 5). 
 
Blocking TLR4 activation:  The method used to block TLR4 activation was adapted 
from Xie et al as follows – A549 cells were seeded into 6-well tissue culture plates and 
grown in the presence of cell culture medium (DMEM, 50 mM HEPES, 8 mM L-
glutamine, and 10% fetal bovine serum).  Confluent A549 cells were washed with and 
kept in the presence of serum-free cell culture medium for 24 hours.  The A549 cells 
were then treated with 10 μg/mL of the monoclonal anti-TLR4 antibody HTA125 
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(cat.#HM2068, Cell Sciences), 10 μg/mL of the isotype control IgG2a (cat.#16-4724-85, 
eBiosciences), or untreated for 1 hour at 37°C.  Following the 1 hour incubation, the cells 
were not stimulated or stimulated with 50 µg/mL LPS (cat.#L5418, Sigma) in the 
presence of serum-free medium for 24 hours.  The cell supernatants were collected, 
subjected to centrifugation at 14,000 rpm for 10 minutes, and stored at -80°C for analysis 
of IL-6 using a sensitive ELISA (cat.#HS600B, R&D Systems).  The data presented 
represent the mean and the standard deviation of the mean derived from at least two 
independent experiments.  TLR4 induces the secretion of IL-6 by A549 cells after 
stimulation by LPS (Figure 6D).  However, in the presence of HTA125, TLR4 is 
inhibited as demonstrated by low levels of IL-6 secretion to levels consistent with 
previous observations (35) (Figure 6D). 
 
Statistical Analysis:  Any differences in the mean values of CMT translocation  
efficiencies or A549 cell cytotoxicity compared between various mutant and WT strains 
were tested for significance by the unpaired t-test (12) and P-values less than 0.05 were 
considered significant. 
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Chapter III 
 
Investigations into the Mechanism of CMT 
 80 
SUMMARY 
 
The discovery of several complex and intricate specialized secretion systems for 
both Gram-negative and positive bacteria suggest translocation of effector proteins into 
host cells is an important component of microbial pathogenesis.  In the process known as 
cytolysin-mediated translocation (CMT), the cholesterol-dependent cytolysin streptolysin 
O (SLO) translocates the S. pyogenes NAD+-glycohydrolase (SPN) into the cytosol of a 
variety of host cell types including the A549 immortal lung carcinoma cells.  However, 
the mechanism used to traffic an S. pyogenes effector protein across the host cell 
membrane into the cytosol remains obscure.  Recent data demonstrates that in the 
absence of a pore, SLO retains the ability to translocate SPN into the host cell cytosol, an 
indication that SPN does not travel through the lumen of the SLO pore as previously 
suggested.  It is currently unknown if a host cell endocytic pathway aids in the process of 
translocating approximately 70% of the total secreted SPN.  In this study, we assessed the 
affects of inhibitors that target host cell endocytosis on CMT.  
Inhibition of the clathrin-dependent endocytic pathway using LY294002 does not 
affect the ability of SLO to translocate SPN.  Furthermore, preliminary data suggests that 
using staurosporine to inhibit a kinase involved with caveolae-dependent endocytosis also 
does not affect CMT.  Surprisingly, a compound that sequesters cholesterol, which is 
thought to be important for cytolysin membrane binding, also does not affect CMT.  By 
contrast, altering the cleavage site of a cysteine protease in the SLO N-terminal extension 
abrogates CMT, suggesting that the N-terminal extension primary structure is critical for 
SPN translocation.  However, a bacterial two-hybrid system based on the restoration of 
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Bordetella pertussis adenylate cyclase (CyaA) activity was unable to detect an interaction 
between SPN and SLO.  In total, while it is still unclear how SPN and SLO interact to 
allow for CMT, it remains possible that a host endocytic pathway is actively involved in 
SPN translocation. 
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INTRODUCTION 
 
 Translocation of bacterial effector proteins into the host cell cytosol occurs via an 
array of methods.  The Type III injectisome machinery of Gram-negative bacteria forms a 
pore in the host cell membrane through which effector translocation occurs (15, 17).  The 
AB5 toxin translocation system of cholera toxin requires the toxin complex to bind to a 
receptor in a cholesterol-enriched membrane domain permitting endocytosis, followed by 
fusion of the vesicle to the endoplasmic reticulum, and retrograde trafficking of the 
effector protein to the host cytosol (7).  A specialized secretion system in Streptococcus 
pyogenes is known as cytolysin-mediated translocation (CMT) and several studies 
provide information about the basic requirements of the process (4, 15, 24, 27).  
However, in contrast to the Gram-negative secretion systems described, many details 
regarding the mechanism of CMT remain elusive. 
 Streptolysin O (SLO) is necessary for translocation of the NAD+-glycohydrolase 
(SPN) into the host cell cytosol (4, 24, 27).  Several models describe the potential 
mechanism of CMT.  The simplest CMT model predicts that SPN diffuses through the 
SLO pore.  However, the following observations suggest that CMT is more complex.  
The ability of wild type (WT) S. pyogenes to translocate approximately 70% of the total 
SPN secreted into the host cell cytosol suggests CMT is likely a directed process that 
leads to a polar distribution of SPN (24, 27).  Co-infections with isogenic slo- and spn- 
mutants are unable to restore SPN translocation, illustrating that it is unlikely CMT 
occurs via SPN diffusion into the host cell (24).  Additionally, the related cytolysin, 
perfringolysin O (PFO), is unable to translocate SPN, again indicating that passive 
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diffusion through the pore is not probable (27).  Furthermore, previous work shows that 
S. pyogenes strains that are unable to adhere to the host cell membrane are also unable to 
translocate SPN, demonstrating that CMT is contact dependent, similar to other 
specialized secretion systems such as the Gram-negative Type III system (24). 
 The previous studies provide data showing that the mechanism of CMT does not 
occur by diffusion through the SLO pore.  An alternative CMT model involves the 
formation of a protected SLO channel that would allow polar translocation of SPN into 
the host cell cytosol.  This possible CMT mechanism would begin with S. pyogenes 
adhering to the host cell membrane, SLO creating a pore in the host membrane, and 
forming a protected channel from the bacterial surface to the surface of the host cell.  
Once made, the channel would permit SPN to directly enter the host cell.  An earlier 
study began to test the channel model by determining if the potential SLO channel could 
selectively translocate substrates.  This study determined that CMT can differentiate 
between SPN and mitogenic factor (MF), another S. pyogenes secreted toxin (14).  
Furthermore, deletions in the primary SPN sequence are intolerable and inhibit CMT 
(14).  In addition, use of the SPN secretion signal sequence is not sufficient to make MF a 
CMT competent substrate (14).  Moreover, a fusion protein encoding the full-length 
primary sequence of SPN followed by the MF primary sequence is the only chimera that 
permits translocation of MF into the host cell cytosol (14).  This suggests the amino 
terminus of SPN might be important for polar translocation during CMT and the 
carboxyl-terminus is necessary for both translocation and enzymatic activity (14).  
Together, the data suggest CMT can distinguish between substrates that would enter the 
potential protected SLO channel.  These data also indicate that SPN is a substrate that 
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actively participates during CMT and that passive diffusion through the SLO pore does 
not occur.   
Unlike most other members of the cholesterol-dependent cytolysin (CDC) family, 
the SLO protein has a 66-residue N-terminal extension, which encodes the cleavage site 
for the S. pyogenes cysteine protease (SpeB) at residue 80 (27, 33).  One other CDC, 
pyolysin from Arcanobacterium pyogenes, has an additional 30 residues at its amino 
terminus following the secretion signal (3, 19).  Deletion of the first 18 residues of the 
SLO N-terminal extension (SLO∆37-54) did not affect CMT suggesting these specific 
residues are not necessary (27).  However, the SpeB cleavage site is present in the 
SLO∆37-54 mutant protein and its requirement for CMT is unclear.  Removal of the entire 
SLO N-terminal extension (SLO∆37-102) abrogates its ability to translocate SPN indicating 
this region is necessary for translocation (27).  Although, the N-terminal extension is 
necessary for SPN translocation it is not sufficient to convert PFO into a CMT competent 
protein (27).  When associated with SLO, the N-terminal extension may have a specific 
confirmation that can bind to SPN and this extension could form the protected channel.  
Previous attempts to detect binding between purified SPN and SLO have been 
unsuccessful.  The inability to observe protein interactions suggests that the purified 
proteins may not have the correct conformation, may not interact efficiently when SLO is 
a monomer, or may require an accessory protein. 
 A recent study illustrates that similar to WT SLO, an SLO mutant protein that 
cannot form pores can conduct CMT (25).  Hence, the SLO pore is unnecessary for SPN 
translocation into the host cell cytosol.  This suggests that SPN does not enter the host 
cell cytosol through the lumen of a protected channel.  Additionally, cytochalasin D 
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inhibition of host cell actin polymerization does not affect CMT, suggesting the host cell 
clathrin-mediated endocytic pathway is not involved (25).  The data from this latest study 
significantly alters the model that describes the mechanism of CMT.  The current model 
now predicts that SLO binds to the membrane and then one of several different host 
pathways might be involved in endocytosis of SPN and SLO or SPN alone.  Following 
endocytosis, the release of SPN from the endocytic vesicle into the cytosol would occur 
by an unidentified mechanism. 
The work described in the following studies focuses on deciphering whether an 
endocytic pathway of the host cell actively participates in CMT.  The cholesterol-
dependent/clathrin-independent endocytic pathway known as CLIC/GEEC, the caveolae-
dependent pathway, and flotillin-dependent pathway are a few examples of endocytic 
pathways that occur independently of clathrin.  To begin addressing this question, we 
used different pharmacological inhibitors that target proteins involved with host cell 
endocytosis.  Although a couple of the inhibitors had no affect on CMT, several 
experiments using inhibitors were inconclusive due to difficulties with drug toxicity.  In 
addition, using a bacterial two-hybrid system we were unable to detect an interaction 
between any portion of SPN and SLO.  We did discover that mutating the SpeB cleavage 
site of SLO inhibits CMT.  Thus, cleavage of the SLO N-terminal extension may be 
necessary or the mutation in the N-terminal extension prevented a critical binding 
interaction required for CMT.  The data presented in this chapter has not been submitted 
for publication. 
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RESULTS 
 
The inhibition of phosphoinositide 3-kinase and protein kinase C do not affect CMT:  
The participation of the mammalian host cell during the process of CMT is unclear.  
Several studies were conducted inhibiting different steps of the host endocytic process to 
determine if the host cell actively participates throughout CMT.  After SLO binds to the 
host cell membrane, there may be transmission of signals into the cell from the 
membrane phospholipids (i.e. phosphatidylinositols).  Phosphatidylinositol (4,5) P2, 
(PtdIns (4,5) P2), involved at the start of many signaling cascades, is important for 
clathrin-mediated endocytosis (23, 37).  Phosphoinositide 3-kinase (PI3-kinase) activity 
on PtdIns is required for the formation of PtdIns (4,5) P2 (23, 37).  To determine if PI3-
kinase activity on PtdIns was necessary for CMT, the inhibitor LY294002 was used to 
treat A549 cells prior to infection with S. pyogenes.  The efficiency of SPN translocation 
was evaluated according to the percent of the total SPN expressed that was translocated 
into the A549 cell cytosol.  Inhibition of PI3-kinase did not affect SPN translocation by 
WT S. pyogenes (Figure 1) suggesting lipid phosphorylation was not necessary and 
corroborating that CMT did not require clathrin-mediated endocytosis. 
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Figure 1:  LY294002 inhibition of phosphoinositide 3-kinase does not affect CMT.  The level 
of SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various 
concentrations of LY294002.  The bars represent the percent of the total SPN expressed that was 
translocated into the A549 cytosolic fraction, after a 3.75 hr infection.  The data presented 
represent the mean and the standard deviation of the mean derived from at least three independent 
experiments. 
 
 
Clathrin-independent endocytosis typically involves host cell signaling molecules, 
which are enriched in cholesterol microdomains.  Staurosporine is a naturally occurring 
compound that generally inhibits serine/threonine kinases, such as protein kinase C 
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(PKC), that phosphorylate proteins required for the process of endocytosis (11, 13).  A 
preliminary experiment treating A549 cells with various concentrations of staurosporine 
prior to infection with WT S. pyogenes was used to assess the role of PKC.  Inhibition of 
PKC did not prevent SPN translocation (Figure 2), suggesting the caveolae-dependent 
pathway may not be necessary. 
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Figure 2:  Staurosporine inhibition of protein kinase C does not affect CMT.  The level of 
SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various 
concentrations of staurosporine.  The bars represent the percent of the total SPN expressed that 
was translocated into the A549 cytosolic fraction, after a 3.75 hr infection.  The data presented 
are from a single experiment. 
 89 
 
Sequestering membrane cholesterol does not affect CMT:  Many of the proteins and 
lipids involved in clathrin-independent endocytic processes are present in cholesterol 
microdomains within the host cell membrane (11).  To ascertain the affects of disrupting 
the cholesterol microdomains on CMT, various concentrations of nystatin were used to 
treat A549 cells before an infection with S. pyogenes.  The ability of WT S. pyogenes to 
translocate SPN was not affected by cholesterol sequestration (Figure 3).  This suggests 
that cholesterol does not have to localize to microdomains for CMT to occur, however, it 
is unknown if reducing levels of cholesterol in the membrane would have an effect on 
CMT. 
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Figure 3:  Nystatin treatment of membrane cholesterol does not affect CMT.  The level of 
SPN translocation by S. pyogenes expressing WT SLO was analyzed in the presence of various 
concentrations of nystatin.  The bars represent the percent of the total SPN expressed that was 
translocated into the A549 cytosolic fraction, after a 3.75 hr infection.  The data presented 
 90 
represent the mean and the standard deviation of the mean derived from at least three independent 
experiments. 
Inhibitors targeting various stages of host cell endocytosis disrupt SPN secretion by 
WT S. pyogenes:  Host cell clathrin-independent endocytosis may require tyrosine 
kinases and endosomal trafficking (11).  Inhibitors were used to evaluate the role of 
tyrosine kinases in CMT.  Genistein is a compound, produced by soybeans, that generally 
inhibits tyrosine kinases and PP2 is a compound that specifically inhibits the Src family 
of tyrosine kinases (1, 2, 10, 16).  To evaluate the role of tyrosine kinases in CMT, A549 
cells were treated with genistein or PP2 prior to an infection with WT S. pyogenes.  
However, numerous attempts to assess the importance of tyrosine kinases were 
unsuccessful; there was a large reduction of total SPN secretion from S. pyogenes in the 
presence of various concentrations of the tyrosine kinase inhibitors.  Additionally, 
experiments treating A549 cells with sodium orthovanadate (tyrosine phosphatase 
inhibitor) and chloroquine (inhibitor of endosomal acidification) before an infection with 
WT S. pyogenes were also inconclusive due to the overall diminished levels of SPN 
secretion in the presence of the inhibitors.  Although, these endocytic inhibitors were 
used at concentrations that affected SPN secretion, altering the concentrations may permit 
their use in future investigations. 
 
Binding between SLO and SPN is undetectable:  Although it is not yet clear which 
clathrin-independent endocytic pathway may participate in CMT, SPN and SLO 
presumably interact during this process.  In a previous study, attempts to precipitate and 
identify interacting partners from S. pyogenes overnight cell-free culture supernatants 
using the SLO antiserum were unsuccessful (26).  Similarly, incubation of cell-free 
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culture supernatants with purified SPN, expressing a 6X histidine tag, also did not isolate 
a binding partner (26).  To investigate further binding between SPN and SLO, we used a 
bacterial two-hybrid technique based on the enzymatic activity of the Bordetella pertussis 
adenylate cyclase (CyaA) (Table 2).  The CyaA enzymatic domain is split into two 
fragments, known as T25 and T18, that when brought together permit synthesis of cyclic 
adenosine monophosphate (cAMP) in DHP1, a strain of  Escherichia coli lacking cyaA  
(21).  In cases which the CyaA fragments are fused to proteins that interact, the 
production of cAMP allows for expression of maltose metabolism genes (21).  Colonies 
that express proteins that complement the production of cAMP appear red on 
MacConkey/maltose agar plates, an indication that the fused proteins interact (22).  
Colonies that appear white or pink on the MacConkey/maltose plates express fused 
proteins that do not bring the CyaA fragments together (22). 
To determine if SPN and SLO interact through the amino terminus of each 
protein, portions of slo and spn were amplified using the primers listed in Table 2 and 
each product inserted into a plasmid containing one of the two CyaA fragments.  In the 
DHP1 E. coli strain, expression of the two CyaA fragments in the absence of interacting 
proteins prevented the production of cAMP and pale colonies grew on the plates (T25 
and T18C, Figure 4).  In contrast, the expression of a leucine zipper domain (control) 
brought the two CyaA fragments together in DHP1 and red colonies appeared indicating 
that cAMP production occurred allowing maltose utilization (T25-zip and T18C-zip, 
Figure 4).  Unlike the leucine zipper domain (control), expression of the SLO N-terminal 
sequence and the SPN amino-terminus did not bring the two CyaA fragments together 
and the colonies were pale in color (Figure 4). 
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Table 1.  Bacterial two-hybrid plasmids. 
Plasmid Relevant genotype/Description Reference 
pKT25 cya1 – 224/Expression vector encoding T25 fragment of CyaA (21) 
pUT18C cya225 – 399/Expression vector encoding T18 fragment of CyaA (21) 
pKT25-zip cya1 – 224-zip/T25 CyaA fragments fused to leucine zipper region of  
a yeast protein  
(21) 
pUT18C-zip cya225 – 339-zip/T18 CyaA fragments fused to leucine zipper region  
of a yeast protein 
(21) 
pKT25-SLO  
N-terminal extension 
cya1 – 224-slo37 – 102/T25 CyaA fragments fused to SLO N-terminal  
extension 
This study  
pUT18C-SPN  
amino-terminus 
cya225 – 339-spn41 – 165/T18 CyaA fragments fused to SPN amino  
terminus 
This study 
pKT25-IFS cya1 – 224-ifs/T25 CyaA fragments fused to full length IFS This study 
pUT18C-SPN cya225 – 399-spn/T18 CyaA fragments fused to full length SPN This study  
pKT25-SPN cya1 – 224-spn/T25 CyaA fragments fused to full length SPN This study  
pUT18C-SLO cya225 – 399-slo/T18 CyaA fragments fused to full length SLO This study 
pKT25-SLO cya1 – 224-slo/T25 CyaA fragments fused to full length SLO This study 
pUT18C-SPN cya225 – 399-spn/T18 CyaA fragments fused to full length SPN This study  
pUT18C-SpyM3-0131 
predicated open reading 
frame 
cya225 – 399-orf 0131/T18 CyaA fragments fused to predicated  
SpyM3-0131 open reading frame 
This study  
pKT25-SpyM3-0131 
predicated open reading 
frame 
cya1 – 225-orf 0131/T25 CyaA fragments fused to predicated  
SpyM3-0131 open reading frame 
 
This study 
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Figure 4:  Interaction between the SLO N-terminal extension and the SPN amino-terminus 
is undetectable.  DHP1 E. coli expressing the two fragments of the adenylate cyclase (CyaA) in 
the presence or absence of interacting proteins were screened on MacConkey-maltose agar plates.  
Red colonies indicate a protein-protein interaction that brings the CyaA fragments together.  
White or pink colored colonies appear when the CyaA fragments are unable to interact.  The 
images shown are representative of data obtained from a single experiment.  The plasmids used to 
express the proteins are listed in Table 1. 
 
 
To ensure that the CyaA bacterial two-hybrid system could detect S. pyogenes 
proteins binding to each other, the nucleotide sequence encoding full length IFS protein 
and the nucleotide sequence encoding full length SPN protein were expressed in the 
DHP1 E. coli strain (Table 1 and 2).  Similar to the leucine zipper domain, IFS and SPN 
were able to interact and brought the two CyaA fragments together to produce red 
colonies on plates (Figure 5).  As expected, the colonies that grew were pale when the 
CyaA fragments were expressed alone (Figure 5).  To determine if SPN and SLO could 
bind to each in the bacterial two-hybrid system, slo and spn were amplified using the 
primers listed in Table 2 and each product inserted into a plasmid containing one of the 
two CyaA fragments.  Attaching SPN to the first CyaA fragment (T25-SPN) and SLO to 
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the second CyaA fragment (T18C-SLO) did not restore cAMP production resulting in 
pale DHP1 E. coli colonies (Figure 5A).  Moreover, swapping the CyaA fragment fused 
to SPN (T18C-SPN) and SLO (T25-SLO) produced pale colonies, indicating that CyaA 
activity was not complemented (Figure 5B).  Thus, the bacterial two-hybrid was unable 
to detect binding between SPN and SLO.   
 
 
Figure 5:  SLO and SPN protein interaction is undetectable in the bacterial two-hybrid 
system.  The ability of SPN and SLO bind to each other and restore CyaA production of cAMP 
was assessed by fusing each protein to a CyaA fragment.  The bacterial two-hybrid data are 
presented as explained in the legend of Figure 4.  MacConkey agar plates were used to visualize 
binding between S. pyogenes proteins.  (A)  The first CyaA fragment was fused to SPN and the 
second CyaA fragment was fused to SLO.  (B)  The first CyaA fragment was expressed with SLO 
and the second CyaA fragment was expressed with SPN.  The images shown are representative of 
data obtained from a single experiment.  The plasmids used to express the proteins are listed in 
Table 1. 
 
 
However, other S. pyogenes proteins might be necessary for SPN and SLO 
binding to occur.  There are several small open reading frames downstream of SLO.  One 
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of these putative genes is present in the same chromosomal location in several S. 
pyogenes strains suggesting it might encode a functional protein.  The putative protein 
encoded by this gene was expressed in the bacterial two-hybrid system to determine if it 
could bind to portions of SLO or SPN.  Co-expression of the putative protein SpyM3-
0131with the SLO N-terminal extension (Figure 6A) or with full length SPN (Figure 6B) 
did not reconstitute the activity of CyaA and lead to the growth of pale colonies.  This 
suggests that these proteins are unable to bind in this system. 
 
 
Figure 6:  Binding of a putative S. pyogenes protein SpyM3-0131 to SLO or SPN is 
undetectable.  The ability of SLO and SPN to bind to the predicated SpyM3-0131 protein in the 
bacterial two-hybrid system was assessed.  Colonies that expressed the predicated protein with 
(A) the SLO N-terminal extension or with (B) full length SPN were pale in color on the 
MacConkey agar plates indicating that CyaA activity was not restored.  The images shown are 
representative of data obtained from a single experiment.  The plasmids used to express the 
proteins are listed in Table 1. 
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Mutation of the SpeB cleavage site in the N-terminal extension inhibits CMT:  SpeB is 
a cysteine protease and its predicated recognition and cleavage site within the SLO N-
terminal extension is MIKLA (28, 33).  The molecular weight of full length SLO is 
approximately 61 kD and the cleaved form is approximately 50 kD (33).  The high 
molecular weight form is the predominant species present in overnight S. pyogenes 
cultures that have grown in the presence of the cysteine protease inhibitor E64.  
To assess the requirement for SpeB cleavage in CMT, the cleavage site sequence 
was changed from MIKLA to MGTLA.  The strain expressing the SLOMGTLA protein was 
used to infect A549 cells.  The efficiency of SPN translocation was evaluated according 
to the percent of the total SPN expressed that was translocated into the A549 cell cytosol.  
As expected, the WT stain was CMT-competent, whereas the SLO- mutant was unable to 
translocate SPN (Figure 7).  Surprisingly, the strain expressing SLOMGTLA mutant protein 
was CMT incompetent similar to the SLO- mutant (Figure 6).  The mutant strain’s 
inability to translocate SPN suggests that SpeB cleavage is necessary.  However, the loss 
of CMT competence may be a result of structural changes in the SLO N-terminal 
extension caused by the mutation. 
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Figure 7:  The SpeB cleavage site is required for SPN translocation.  The ability of 
the SLO N-terminal extension mutant to translocate SPN into the A549 cell was 
analyzed.  The bars represent the percent of the total SPN expressed that was translocated 
into the A549 cytosolic fraction, after a 3.75 hr infection.  The data presented represent 
the mean and the standard deviation of the mean derived from at least three independent 
experiments. 
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DISCUSSION 
 
The studies detailed in this chapter were conducted to begin elucidating the SLO-
mediated mechanism of SPN translocation.  The recent discovery that pore-forming 
mutants of SLO retain the ability to translocate SPN suggests that the host cell is an 
active participant during CMT and that some form of endocytosis might be involved.  We 
used various pharmacological inhibitors to begin assessing the role of the host cell during 
CMT.  Previous reports indicate that treating host cells with inhibitors of actin 
polymerization do not affect CMT (4, 24).  Clathrin-dependent endocytosis depends on 
both actin polymerization and the presence of PtdIns(4,5)P2 in the host membrane (6).  
We further investigated the importance of this pathway in CMT using an inhibitor to PI3-
kinase.  Data presented here demonstrates that intracellular signaling through PI3-kinase 
phosphorylation of lipids is not required for CMT (Figure 1).  However, control 
experiments assessing the ability of LY294002 to inhibit PI3-kinase in A549 cells need to 
be done.  Together, the data from the previous actin polymerization and the current PI3-
kinase studies suggest that the host cell clathrin-dependent pathway of endocytosis is not 
necessary for SPN translocation.   
There are several clathrin-independent endocytosis pathways and 
pharmacological inhibitors can target specific stages of the mechanisms.  Caveolae-
dependent pathway is an example of a clathrin-independent endocytosis.  PKC activity 
has been implicated in the caveolae-dependent pathway.  Preliminary experiments with 
the serine/threonine kinase inhibitor, staurosporine, suggest that PKC activity is not 
necessary for CMT (Figure 2).  However, this experiment should be replicated to confirm 
 99 
this result and control experiments must be done to determine if staurosporine effectively 
inhibits PKC. 
A common characteristic of clathrin-independent endocytosis is the requirement 
for cholesterol microdomains (11).  The ability of CMT to occur in the presence of 
nystatin, an inhibitor that sequesters cholesterol, suggests that cholesterol does not have 
to be in microdomains.  However, based on this study the requirement for cholesterol 
cannot be eliminated.  Additional experiments using an inhibitor that extracts cholesterol, 
methyl-β-cyclodextrin, or using SLO mutants that cannot bind to cholesterol will be 
necessary to address definitively the requirement of cholesterol in CMT. 
Attempts to inhibit other steps of clathrin-independent endocytosis were 
unsuccessful.  A concentration range of 100 μM to 400 μM of genistein, a general 
tyrosine kinase inhibitor, prevents S. pyogenes SPN secretion during an infection as the 
drug concentration increases.  A caveat to these experiments is that genistein inhibits the 
growth of Staphylococcus aureus and other bacteria (18, 40).  However, previous studies 
used the listed range of genistein concentrations to investigate host cell internalization of 
S. pyogenes and host cell signaling in the presence of S. pyogenes (30, 31, 34).  One study 
reported that concentrations higher than 250 μM affect S. pyogenes viability (34); 
however, none of the studies using genistein assessed the affects of the inhibitor on 
protein secretion.  Genistein has an apparent half maximal inhibitory concentration 
(IC50) of 2.6 μM against some tyrosine kinases (9).  Other studies have successfully used 
genistein concentrations of 30 μM and 60 μM to inhibit tyrosine kinase activity, 
suggesting that genistein has a high potency (12, 41).  Therefore, future studies should 
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use lower concentrations to avoid any deleterious effects on bacterial growth and protein 
secretion.   
Efforts to assess if PP2, a specific inhibitor of the Src family of tyrosine kinases, 
affect CMT were also inconclusive.  Prior to an infection, cells were treated with a PP2 
concentration range of 5 μM to 15 μM.  All concentrations of PP2 in this range inhibited 
SPN secretion by S. pyogenes.  However, the concentrations tested may have been too 
high, as the IC50 for PP2 is as low as 4 nM for some members of this tyrosine kinase 
family and as high as 100 nM for other members (16).  Similar affects on S. pyogenes 
SPN secretion were observed when sodium orthovanadate and chloroquine were used to 
pretreat host cells.  An increase in the concentration of sodium orthovanadate, a general 
inhibitor of tyrosine phosphatases, ranging from 10 μM to 100 μM coincides with 
decreasing amount of SPN secretion during the infection.  Chloroquine, makes the pH 
environment of endocytic vesicles more basic, to affect vesicle trafficking and fusion 
with the lysosome (39).  However, there are reports that chloroquine has antibacterial 
activity and has the ability to affect DNA and protein synthesis (8, 29, 35).  The 
chloroquine studies with S. pyogenes and A549 cells used between 100 μM to 300 μM 
concentration, which appear to effect protein secretion.  Overall, the various 
pharmacological inhibitors appear to inhibit S. pyogenes SPN secretion.  Alternative 
compounds such as okadaic acid and calyculin A, both which inhibit serine/threonine 
phosphatases, and bafilomycin A, which increases pH of endosomes, can be used in the 
future to assess the effect on CMT.  SPN translocation by SLO may use a retrograde 
trafficking mechanism similar to the AB5 toxin family of proteins.  Compounds such as 
brefeldin A and golgicide A (36) could be used to reveal the role of retrograde 
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trafficking.  Future experiments using the previously tested inhibitors should use lower 
concentrations of the reagents.  Experiments should also assess SPN secretion in the 
presence of the prospective and previously tested compounds, which provided 
inconclusive data. 
Previous experimental efforts did not detect binding between SPN and SLO using 
purified proteins in a column pull-down assay (26).  The current attempts using a 
bacterial two-hybrid system, based on restoring the activity of CyaA from B. pertussis, 
were also unsuccessful.  The bacterial two-hybrid system did detect an interaction 
between SPN and IFS, suggesting that it is useful to probe for binding between S. 
pyogenes proteins.  However, there was no detection of a binding interaction between the 
amino-terminus of SPN and the SLO N-terminal extension or between full length SPN 
and full length SLO.  It is possible that SPN only interacts with SLO when it is an 
oligomer.  However, the ability of a monomer-locked form of SLO to translocate SPN 
suggests that oligomerization might not be necessary for these two proteins to interact 
(25).  An accessory molecule, such a host protein, might be important for these two to 
bind.  This accessory protein presumably would bind to both SPN and SLO.  The protein 
product of a small putative gene downstream of SLO was tested for its ability to bind to 
SLO and SPN.  This protein was unable to interact with SLO or SPN in the bacterial two-
hybrid.  Nevertheless, there might be an accessory protein important for binding to occur 
between SPN and SLO. 
Mutation of the SpeB cleavage site significantly decreases CMT, suggesting that 
cleavage of SLO must occur or that changes in the sequence prevent the amino-terminus 
from possibly binding to its partner.  Future experiments to elucidate the role of this site 
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in the N-terminal extension could include using the cysteine protease inhibitor E64 
during an infection.  In addition, two S. pyogenes strains have been made that could be 
used to assess the role of the SpeB cleavage site in CMT.  The first strain expresses a 
point mutation in the SpeB active site (C192S) and the second strain has a deletion of the 
first 40 residues of N-terminal extension (SLO∆37-77).  Using these strains to infect host 
cells will help elucidate the role of the SpeB cleavage site in SLO. 
Taken together, the various studies discussed in this section further characterize 
the mechanism of SPN translocation.  Future work will entail ascertaining 1) the role of 
the SpeB cleavage site, 2) which host cell endocytic pathways might be necessary, and 3) 
determining how SLO binds to SPN. 
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MATERIAL AND METHODS 
 
Table 2.  Primers used in this study. 
 
Name Sequence/Description a 
pKT25-SLO Fwd 
pKT25-SLO Rev 
AAAAAAAATCTAGA
AAAAAAA
GGAATCGAACAAACAAAACACTGC 
GGTACC
Primers to amplify the slo N-terminal extension from pABG5 for insertion into pKT25  
CGTTACTTTTTTTTGTCTTCTGACTTTTTTTC 
(pKT25-SLO N-terminal extension) 
pUT18C-SPN Fwd 
pUT18C-SPN Rev 
AAAAAAAACTGCAGGGTTAGTGGCAAAGAAAACAAAAAAAG 
AAAAAAAGGATCC
Primer to amplify the spn amino-terminus domain from pJOY7 (pABG5-spn-ifs) for insertion into 
pUT18C (pU18C- SPN amino-terminus) 
TATTTATCAATCTCAATGTGATGCGG 
pKT25-SLO Fwd 
NM024p 
AAAAAAAATCTAGA
AAAAAAA
GGAATCGAACAAACAAAACACTGC 
GGTACC
Primers to amplify slo from pABG5 for insertion into pKT25 (pKT25-SLO) 
CGTTACTTATAAGTAATCGAACCATATGGGC 
pUT18C-SPN Fwd 
pUT18C-SPN Rev 2 
AAAAAAAACTGCAG
AAAAAAA
GGTTAGTGGCAAAGAAAACAAAAAAAG 
GGATCC
Primers to amplify spnG330D from pJOY44 (pABG5-spn-ifs) for insertion into pUT18C (pUT18C-SPN) 
TACTTCCTATCTTGCATTCTATCTTGCATTTTC 
NM008p  
NM009p 
AAAAAAAAGGATCC
AAAAAAAAAA
CGTTAGTGGCAAAGAAAACAAAAAAAG 
GGTACC
Primers to amplify spnG330D from pJOY44 (pABG5-spn-ifs) for insertion into pKT25 (pKT25-SPN) 
CGTTACTTCCTATCTTGCATTCTATCTTGCATTTTC 
pKT25-SLO Fwd 
NM024p 
AAAAAAAATCTAGA
AAAAAAA
GGAATCGAACAAACAAAACACTGC 
GGTACC
Primers to amplify slo from pABG5 for insertion into pUT18C (pUT18C-SLO) 
CGTTACTTATAAGTAATCGAACCATATGGGC 
pKT25-IFS Fwd 
pKT25-IFS Rev 
AAAAAAAAAGGATCC
AAAAAAAAA
CATGTATAAGGTGCCAAAGGGTTTAGAAC 
GGTACC
Primers to amplify ifs from pJOY7 (pABG5-spn-ifs)  for insert into pKT25 (pKT25-IFS) 
CGTTAAAATGTTTCTATTGTTCTTTCGACC 
NM017p 
NM018p 
AAAAAAAAGGATCC
AAAAAAA
CAATGAGGCAGTAGCTACTCAAGCATGTGCAGATGGAACAAAT 
GGTACC
Primers to amplify SpyM3-0131 from JRS4 chromosomal DNA for insertion into pKT25 or pUT18C 
CGTTATTTTGTGACTGTATCCGTAGTAGGCTG 
a Sequence is shown 5’ to 3’.  Engineered restriction endonuclease sites are underlined. 
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Table 2.  Primers used in this study continued. 
 
Name Sequence/Description a 
Kpn1 Fwd 
Kpn1 Rev 
AAAAAAGGTACC
AAAAAA
CTTGCTCCCAAAGAAATGCC 
GGTACC
Inverse PCR primers used to make the N-terminal extension mutant SLOMGTLA from pMAM1.4 (27) 
CATATCGTTAGAGTTAAGC 
NM300p 
MAM6 
AAAAAAAAACTCGAG
CTGCTCGC
GAATGATAAAAAGGTATGAAGG 
ATCGAT
Primers to insert the sequence of the N-terminal extension mutant SLOMGTLA into a temperature sensitive 
plasmid 
CTACTTATAAGTAATCGAACCA 
a Sequence is shown 5’ to 3’.  Engineered restriction endonuclease sites are underlined. 
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Bacterial strains:  Molecular cloning experiments used Escherichia coli TOP10 cells.  
The studies with Streptococcus pyogenes utilized the M serotype 6 strain JRS4 (38). 
Routine culture of S. pyogenes and E. coli was conducted as previously described (27).  
Where appropriate, chloramphenicol or erythromycin was added to media at final 
concentrations of 15 μg/ml for E. coli and 3 μg/ml for S. pyogenes or 750 μg/ml for E. 
coli and 1 μg/ml for S. pyogenes, respectively.  
 
Analysis of CMT:  Streptococcal cultures were grown overnight in ThyB at 37°C, 
subjected to centrifugation, washed twice with 1X phosphate saline buffer (PBS), and 
resuspended in pre-warmed cell culture medium (DMEM with glucose, 8 mM L-
glutamine, 50 mM HEPES, and 10% heat inactivated fetal bovine serum) to an OD600 of 
0.875 in a Shimaduzu UVmini or to an OD600 of 0.66 in a Beckman Coulter DU730.  
Confluent A549 cells were infected with 1 mL of the resuspended streptococcal strains 
for 3.75 hrs.  After the infection, the culture supernatant was sterilized using a 0.2-micron 
filter unit.  The A549 cells were washed twice with 1X PBS and lysed with a 1X PBS-
0.05% saponin solution containing a mini complete protease inhibitor tablet 
(cat.#1836153, Roche) at 37°C for 5 minutes.  The cytosolic fractions subjected to 
centrifugation at top speed for 10 minutes at 4°C, followed by an ultracentrifugation at 
135,380 x g for 1 hr at 4°C.  SPN activity in the A549 cytosolic fraction was analyzed as 
described earlier (24).  When indicated, LY294002 (10 µM, 50 µM, 100 µM; 
cat.#440204, EMD Chemicals), staurosporine (0.5 µM, 1 µM; cat.#569396, EMD 
Chemicals), and nystatin (5 µg, 25 µg; cat.#N6261, Sigma Aldrich) were incubated with 
the A549 cells at for 1 hr prior to infection.  Genistein (cat.#345834, EMD chemicals), 
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PP2 (cat.#529576, EMD Chemicals), sodium orthovanadate (cat.#450243, Sigma 
Aldrich), and chloroquine (cat.#C6628, Sigma Aldrich) were used to pretreat A549 cells 
to assess the effects on CMT. 
 
Manipulation and computational analyses of DNA:  Transformation of E. coli and 
plasmid DNA isolation were performed as previously described (5). Construction of S. 
pyogenes SLOMGTLA mutant was conducted using standard methods (27).  An inverse 
PCR was used to generate the slo mutant allele (sloMGTLA) from the pMAM1.4 template 
(27) with the primers listed in Table 2.  The mutant allele was amplified from pABG5 
using the primers in Table 2 and inserted into pJRS233, a temperature-sensitive vector 
containing an erythromycin resistance cassette (32).  The WT slo allele in JRS4 was 
substituted with the mutant allele using allelic replacement as previously described (20).  
Restriction endonucleases, ligases, and polymerases used according to manufacturer’s 
recommendations.  DNA sequencing analyses performed by a commercial vendor 
(SeqWright; Galveston, TX) validated the fidelity of all DNA sequences created by PCR. 
 
Construction of Bordetella pertussis bacterial two-hybrid fusion plasmids:  The 
plasmids pKT25, pUT18C, and pUT18 (multiple cloning site at the amino-terminus) 
were obtained from the Vogel Lab courtesy of the Dr. Daniel Ladant (21).  Control 
plasmids expressing a yeast zipper protein, pKT25-zip and pUT18C-zip, were also 
provided (21).  Construction of the fusion genes was done using standard methods (27).  
The various bacterial two-hybrid plasmids were made using the primers and templates 
listed in Table 2.  The pKT25 expression vector contained a kanamycin cassette (added to 
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media at final concentration of 50 μg/mL) and the pUT18C expression vector contained 
an ampicillin cassette (added to media at final concentration of 100 μg/mL) (22).  The 
restriction endonucleases, ligases, and polymerases were used according to 
manufacturer’s recommendations.  Transformation of the TOP10 E. coli and plasmid 
DNA isolation were performed as previously described (5).  As previously stated, use of 
the restriction endonucleases, ligases, and polymerases followed the manufacturer’s 
recommendations.  DNA sequencing analyses performed by a commercial vendor 
(SeqWright; Galveston, TX) validated the fidelity of all DNA sequences created by PCR. 
 
Analysis of the bacterial two-hybrid fusion plasmids:  The cyaA- E. coli strain DHP1 
was obtained from Dr. Joseph Vogel’s laboratory courtesy of the Dr. Daniel Ladant (21).  
Co-transformation of the DHP1 E. coli with pKT25 and pUT18C derived plasmids was 
performed using standard methods (27).  Bacteria were grown at 30°C on MacConkey 
(cat.#281810, BD Difco) agar plates supplemented with 1% maltose (cat.#216830, BD 
Difco) in the presence of kanamycin (50 μg/mL) and ampicillin (100 μg/mL).  Following 
the appearance of colonies, individual colonies were restreaked on fresh 
MacConkey/maltose plates containing both antibiotics and grown at 30°C. 
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Chapter IV 
 
Specificity of Streptolysin O Domain 4 in  
Cytolysin-Mediated Translocation 
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SUMMARY 
 
The process of microbial pathogenesis typically involves secretion of toxic 
proteins into host cells.  Transport of bacterial effector proteins occurs through various 
secretion systems and one common feature is the use of translocator.  Cytolysin-mediated 
translocation (CMT) of Streptococcus pyogenes uses streptolysin O (SLO) to translocate 
the S. pyogenes NAD+-glycohydrolase (SPN) into the host cell cytosol.  While SLO is 
required for SPN translocation and can perform this activity without forming a pore, the 
details regarding the basis of this specificity and the contacts made with the host cell 
membrane are unknown.  In the current study, we assessed the requirement and 
specificity of SLO domain 4 binding to the host cell membrane.  Through a series of 
domain 4 swaps between SLO and related cytolysins, we found that although binding is 
necessary it is not sufficient for CMT.  We show that a SLO/PFO domain 4 chimera is 
unable to conduct CMT.  However, a specific primary structure of SLO domain 4 can 
restore CMT activity to the SLO/PFO domain 4 chimera.  Although, reducing the levels 
of cholesterol in the membrane do not affect CMT, mutations that interrupt cholesterol 
binding indicate the sterol does increase the efficiency of CMT. 
 
Manuscript in Preparation 
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INTRODUCTION  
 
The translocation of toxic effector proteins into the host cell is an important part 
of microbial pathogenesis.  Trafficking of bacterial toxins generally requires a secretion 
system that has a dedicated translocator.  Many Gram-negative bacteria direct toxins 
across the plasma membrane into the host cell cytosol using specialized secretion 
systems, such as the Type III secretion system, which has a needle complex and a 
translocator comprised of three proteins (25). Other toxins, like anthrax and diphtheria 
toxins, gain access to the cytosol through the endocytic pathway, after the specific 
translocator binds to the plasma membrane to allow endocytosis of the translocator-toxin 
complex (5, 32, 39).  The Gram-positive bacterium Streptococcus pyogenes uses a 
process denoted as cytolysin-mediated translocation (CMT) to transport an effector 
protein into the host cell.   
During CMT, streptolysin O (SLO) is required for the directed translocation of 
the S. pyogenes NAD+-glycohydrolase (SPN) across the host cell membrane into the host 
cell cytosol (3, 22, 24).  SPN is an enzyme that cleaves β-NAD+ to produce nicotinamide 
and ADP-ribose; however, SPN does not possess cyclase or ADP-ribosyl transferase 
activities as previously described (8, 20, 36).  Both SPN and SLO are part of the large 
collection of virulence proteins secreted during an S. pyogenes infection, which can lead 
to many types of clinical diseases such as pharyngitis, necrotizing fasciitis, and 
glomerulonephritis.  Earlier reports indicate that the majority of SPN secreted is present 
in the host cytosol, that co-infection with isogenic slo and spn mutants cannot reconstitute 
CMT, and that S. pyogenes mutants deficient in either protein are less cytotoxic and less 
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virulent  (2, 3, 22, 24).  Although SLO is necessary for polar translocation of SPN, the 
foundation of this specificity remains elusive.  
The original CMT model predicts SLO forms a pore in the host cell membrane 
and SPN diffuses through the lumen of the pore to enter the host cell cytosol.  However, 
extensive data suggests the process is more complex.  First, SLO has an additional 66 
residues at its amino terminus in comparison to related proteins and removal of this 
sequence abrogates the ability of SLO to translocate SPN, but does not affect SLO pore 
formation (24).  Second, further research illustrates that the related cytolysin 
perfringolysin O (PFO) is not CMT-competent when expressed from a SLO- strain of S. 
pyogenes, even though it can form pores (24).  Third, grafting the SLO N-terminal 
extension onto PFO cannot restore SPN translocation (24).  Hence, the SLO N-terminal 
extension is required but it is insufficient at making a related protein CMT-competent.  
Consequently, the inability of the pore-forming PFO protein to translocate SPN creates 
uncertainty about the role of pore formation during CMT.  
A recent study used two S. pyogenes strains expressing different SLO mutations 
to assess the importance of pore formation in CMT.  One mutant expresses an SLO 
protein locked in a state known as the prepore-complex, in which SLO can form 
oligomers on the host cell surface but cannot insert the complex into the host cell 
membrane (23). The second mutant expresses an SLO protein locked in the monomer 
state and this protein can bind to the host cell surface but is unable to oligomerize (23). 
Neither the prepore- nor the monomer-locked SLO proteins are capable of forming pores 
in host cells.  However, similar to wild type, the prepore-locked strain is CMT-competent 
(23). The monomer-locked strain also retains the ability to translocate SPN, though SLO 
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oligomerization enhances CMT (23). Additionally, deletion of the N-terminal extension 
from the prepore-locked SLO protein abolishes CMT indicating that the pore-forming 
mutant and wild type (WT) SLO use an indistinguishable mechanism to translocate SPN 
(23). In total, these studies demonstrate that pore formation is unnecessary for CMT 
indicating that poration and translocation are two independent SLO activities.  The ability 
of SLO to translocate SPN in the absence of a pore suggests that the contacts made with 
the host cell membrane might be crucial for CMT. 
SLO, PFO, and intermedilysin (ILY) are representatives of the cholesterol-
dependent cytolysin (CDC) family of proteins (15). The CDCs are large oligomeric pore-
forming proteins expressed and secreted by several species of pathogenic Gram-positive 
bacteria (37). These proteins share approximately 40 to 70% amino acid similarity and 
previous analysis of resolved crystal structures illustrate that all members of the family 
likely have 1) an analogous fold that creates four discontinuous domains and 2) a similar 
pore-forming mechanism (1, 12, 28, 30).  Domain 4 of the CDCs is the only portion of 
the protein to be encoded by a continuous primary structure.  Each cytolysin monomer 
makes the initial contact with the host cell membrane via domain 4 of the protein (14, 29, 
38).  This domain contains loops that bind to cholesterol and a tryptophan rich motif 
called the undecapeptide (6, 34, 35).  
Cholesterol has an important role in the cytolysin-membrane interactions.  It is 
evident from a number of studies that the membrane receptor for PFO is cholesterol (7, 
10, 14, 35).  It is also known that pore formation by ILY and SLO requires the presence 
of cholesterol in the membrane; specifically the cholesterol binding loops of domain 4 
must insert into the membrane to complete the pore formation process (10, 34, 35).  
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However, the PFO requirement for cholesterol is not limited to pore formation but 
encompasses the ability of PFO to bind to the host cell membrane (16).  Unlike PFO, the 
receptor for ILY is CD59, a membrane anchored regulatory protein that inhibits a pore-
forming complex activated by the immune system from attaching to the surface of human 
cells (11, 18, 21, 34).  The majority of the cytolysins are capable of binding and lysing 
cells from many mammalian species.  However, the activity of ILY is restricted to human 
cells and domain 4 confers this specificity (10, 26-28).  The ubiquitous presence of CD59 
on human cells also supports the specific action of ILY.  Although ILY binds to CD59 to 
form the prepore-complex, the cytolysin must also bind to cholesterol because as the 
prepore-complex enters the membrane to form a pore the cytolysin disengages from its 
receptor CD59 (21). 
While the membrane receptor is unknown, SLO can bind to membranes with 
reduced levels of cholesterol similar to ILY (10). Specific mutations in the cholesterol 
binding loops of domain 4 decrease the ability of SLO to bind to cholesterol (6). 
However, the function and importance of contact with cholesterol in the membrane 
during CMT is unknown.  We explore the role of receptor specificity and membrane 
interactions on CMT using domain 4 swaps made between SLO and related cytolysins.  
These studies reveal that CMT does depend on domain 4 specificity.  In addition, 
reducing membrane cholesterol, to levels that inhibit binding of PFO domain 4, does not 
affect CMT.  Furthermore, mutating the first cholesterol-binding loop demonstrates that 
cholesterol is not necessary but it does enhance CMT. 
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RESULTS 
 
Binding to host cell membranes is necessary for SLO to translocate SPN:  To ascertain 
the role of domain 4 in CMT, an in-frame deletion in slo was generated to create a mutant 
protein lacking the domain (SLOΔD4, Table 1).  Western blot analysis showed that 
compared to WT, the resulting mutant was secreted, soluble, and stable (Figure 1A).  
Following an infection with the WT and SLOΔD4 expressing strains, A549 cells were 
fractionated using Triton X-100 and evaluated using a Western blot.  WT SLO localized 
to the Triton X-100 insoluble cell membrane fraction, however, SLOΔD4 did not localize 
to the A549 cell membrane (Figure 1B) indicating this domain was needed to bind to host 
cells.  In addition, unlike WT SLO, cell-free overnight culture supernatants from the 
strain expressing SLOΔD4 did not result in lysis of rabbit erythrocytes (Figure 1C).  To 
determine the requirement for domain 4 in CMT, the SLOΔD4 strain was used to infect 
A549 cells for 3.75 hrs.  The efficiency of SPN translocation was assessed according to 
the percent of the total SPN expressed that was translocated into the A549 cell cytosol.  
As expected, the WT strain was CMT-competent with most (typically >70%) of the total 
SPN expressed present in the A549 cell cytosolic fraction (Figure 1C).  In contrast, 
SLOΔD4 strain was CMT deficient similar to the SLO- strain (Figure 1C).  Thus binding to 
the host cell membrane is necessary for CMT; however, the question is whether it is 
sufficient for SPN translocation to occur.  
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Table 1.  Bacterial stains used in this study. 
Strain Relevant genotype/Description Reference 
JRS4 wild type; WT 
WT SLO 
(33) 
SLO6 slo113-447; SLO- 
SLO deficient mutant 
(31) 
NGM4 slo466-574; SLO∆D4 
SLO lacking the domain 4 
This study 
NGM5 slo1-463 ily417-532; SLO/ILYD4 
SLO domain 1 – 3 sequence and ILY domain 4 sequence 
This study 
NGM6 slo1-463 ily417-532, G485E, A486C, P493W; SLO/ILYD4-ECW 
SLO domain 1 – 3 sequence and ILY domain 4 sequence with typical undecapeptide 
This study  
NGM7 slo1-463 pfo390-500; SLO/PFOD4 
SLO domain 1 – 3 sequence and PFO domain 4 sequence 
This study 
NGM8 slo1-463 pfo390-500, D469K, S472D, Y474R, P477K, T479S, N480K, N481E; SLO/PFOD4-swap1 
SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 1 sequence 
This study 
NGM9 slo1-463 pfo390-500, T427R, Q433Y, H438P, E446G; SLO/PFOD4-swap2 
SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 2 sequence 
This study  
NGM10 slo1-463 pfo390-500 F406Y, V408I, A409L, V413I, S414N, K417D, E418K, N420K, L423I, H425K, K426R, T427R,  
G430N, Y432W, Q433Y, D434S, A437S, H438P; SLO/PFOD4-swap3 
SLO domain 1 – 3 sequence and PFO domain 4 sequence with SLO swap 3 sequence 
This study 
NGM11 sloL565G; SLOL565G 
Mutation in cholesterol binding loop 
This study 
NGM12 sloL565D; SLOL565D 
Mutation in cholesterol binding loop 
This study 
NGM13 slo1-102 pfo48-389 slo464-565; SLONT;D4/PFO 
SLO N-terminal extension sequence, PFO sequence, and SLO domain 4 sequence 
This study 
a Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the 
mutant alleles. 
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Figure 1:  SLO Domain 4 is important for binding and CMT.  (A) Cell-free overnight S. 
pyogenes culture supernatant from the WT, SLO-, and SLOΔD4 were precipitated on ice with 10% 
trichloroacetate and analyzed by a Western blot using anti-SLO antiserum.  (B) Following a 3.75 
hr infection with the WT, SLO- and SLOΔD4 strains, A549 cells were subjected to fractionation 
using Triton X-100.  Shown is a Western blot analysis of the insoluble fraction, along with a 
protein precipitate prepared from an overnight culture supernatant (precipitated SLO).  The image 
shown is representative of data obtained from three independent experiments.  (C) The ability of 
the SLOΔD4 strain (Table 1) to translocate SPN into the A549 cell (top) and hemolytic titers 
(bottom) were analyzed.  The bars show the percent of the total SPN expressed that was 
translocated into the A549 cytosolic fraction, after a 3.75-hour infection.  An ‘*’ indicates that 
CMT is significantly lower than WT (P<0.05).  N.D. denotes the limit of detection for hemolytic 
activity using an undiluted sample.  The data presented represent the mean and the standard 
deviation of the mean derived from at least three independent experiments. 
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The domain 4 sequence of ILY is unable to restore CMT:  An alignment of the domain 
4 primary sequence shows SLO and ILY are 34.7% identical and 49.6% similar, while 
SLO and PFO are 64.5% identical and 74.5% similar (Figure 2).  
 
 
SLO (464) SGKINLSHQGAYVAQYEILWDEINYDDKGKEVITKRRWDNNWYSKTSPFSTVIPLGANSR (524)
PFO (390) KGKINLDHSGAYVAQFEVAWDEVSYDKEGNEVLTHKTWDGNYQDKTAHYSTVIPLEANAR (450)
ILY (417) DGALTLNHDGAFVARFYVYWEELGHDADGYETIRSRSWSGNGYNRGAHYSTTLRFKGNVR (477)
.* :.*.*.**:**:: : *:*:.:* .* *.: : *..* .: : :**.: : .* *
SLO (525) NIRIMARECTGLAWEWWRKVIDERDVKLSKEINVNISGSTLSP-YGSITYK---- (574)
PFO (451) NIRIKARECTGLAWEWWRDVISEYDVPLTNNINVSIWGTTLYP-GSSITYN---- (500)
ILY (478) NIRVKVLGATGLAWEPWRLIYSKNDLPLVPQRNISTWGTTLHPQFEDKVVKDNTD (532)
***: . .****** ** : .: *: * : *:. *:** * . . :
 
 
 
Figure 2:  Domain 4 of SLO is similar to PFO: An amino acid sequence alignment of domain 4 
from SLO, PFO, and ILY was generated using the CLUSTALW2 algorithm.  An asterisk ‘*’ 
below the alignment denotes identical amino acids, while ‘.’ and ‘:’ denote similar and highly 
similar residues respectively.  The dark bar above the SLO sequence indicates the undecapeptide 
sequence.  The underlined amino acids in ILY sequence indicate the atypical residues present in 
the undecapeptide sequence.  The dark bars over the PFO sequence indicate the residues changes 
in the SLO/PFOD4-swap1 and SLO/PFOD4-swap3 strains, while the dark circles indicate the residues 
changes in the SLO/PFOD4-swap2 strain.  The box denotes three cholesterol-binding residues, which 
are located at the tip of three loops in domain 4 of cytolysins. 
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ILY and SLO are similar in their capability to bind to membranes after cholesterol 
extraction (10). Recent reports indicate domain 4 of ILY binds to both CD59 and 
cholesterol (11, 21).  While domain 4 of SLO is required for the process of CMT, it is 
unclear if specific interactions with the membrane are necessary.  To address this 
question, a chimera expressing the domain 4 sequence from ILY in lieu of the WT SLO 
sequence was made to assess the specificity of the region (SLO/ILYD4, Table 1).  
Resembling WT SLO, the SLO/ILYD4 protein was localized to the Triton X-100 
insoluble cell membrane fraction following an infection (Figure 3A) illustrating that the 
protein was expressed and could bind to A549 cell membranes.  As expected, the 
SLO/ILYD4 protein present in culture supernatants was unable to lyse rabbit erythrocytes 
but retained hemolytic activity against human erythrocytes (Figure 3B).  This data 
demonstrated that the SLO/ILYD4 protein gained the innate activity of the ILY domain 4 
and suggested that the SLO/ILYD4 chimera protein was likely binding to the native 
receptor CD59.  An infection with A549 cells was used to determine if the SLO/ILYD4 
strain also retained the ability to carry out CMT.  Even though membrane binding was 
maintained, the strain expressing the SLO/ILYD4 chimera was unable to translocate SPN 
into the A549 cell cytosol (Figure 3B). 
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Figure 3:  SLO/ILYD4 mutant allows membrane binding but is insufficient in conducting 
CMT.  (A) A Western blot analysis of the Triton X-100 insoluble fractions from A549 cells that 
were infected for 3.75 hr with the indicated strains is shown, along with a protein precipitate 
prepared from an overnight culture supernatant.  The image shown is representative of data 
obtained from three independent experiments.  (B) The SLO/ILYD4 strain (Table 1) was tested for 
CMT efficiency (top) and hemolytic titers (bottom) and the data is presented as described for 
Figure 1.  An ‘*’ indicates that CMT is significantly lower than WT (P<0.05).  N.D. denotes the 
limit of detection for hemolytic activity using an undiluted sample.  The data presented represent 
the mean and the standard deviation of the mean derived from at least three independent 
experiments. 
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In comparison to other cytolysins, domain 4 of ILY has a variant undecapeptide sequence 
with three amino acid differences (26).  The undecapeptide is important for stabilizing 
cytolysins in the host cell membrane (28, 34).  An alternative chimera replacing the three 
variant residues in the undecapeptide of the SLO/ILYD4 protein was created to assess if 
there would be a gain of CMT function (SLO/ILYD4-ECW, Table 1).  The SLO/ILYD4-ECW 
protein was present in the Triton X-100 insoluble fractions suggesting it was able to bind 
to cell membranes (Figure 4A), but was unable to lyse any erythrocytes (Figure 4B).  The 
loss of detectable hemolytic activity suggests that the chimera protein might be unable to 
bind properly to the membrane.  Additional experiments showed that the SLO/ILYD4-ECW 
strain was similar to the SLO- strain and translocated significantly less SPN than WT 
SLO strain (Figure 4B; P<0.05).  Thus, even though the SLO/ILYD4 and SLO/ILYD4-ECW 
proteins maintained the ability to bind to A549 cells, it was apparent that solely binding 
the membrane was not sufficient for CMT and that swapping the domains abrogated the 
ability of SLO to translocate SPN. 
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Figure 4:  SLO/ILYD4-ECW mutant does not restore CMT.  (A) A Western blot analysis of the 
Triton X-100 insoluble fraction along with a precipitate is shown and presented as described for 
Figure 1.  (B) The SLO/ILYD4-ECW strain (Table 1) was tested for CMT efficiency (top) and 
hemolytic titers (bottom) and the data is presented as described for Figure 1.  An ‘*’ indicates that 
CMT is significantly lower than WT (P<0.05).  N.D. denotes the limit of detection for hemolytic 
activity using an undiluted sample.  The data presented represent the mean and the standard 
deviation of the mean derived from at least three independent experiments. 
  
131 
 
Despite the level of sequence homology, SLO and PFO binding is not the same:  The 
large degree of variability (49.6%, Figure 2) between the domain 4 sequence of SLO and 
ILY may have affected the ability of the SLO/ILYD4 protein to translocate SPN.  Since 
SLO and PFO have a higher degree of sequence similarity in the region of domain 4 
(74.5%, Figure 2), it was feasible that this sequence could functionally serve as a 
replacement.  To test this premise, a chimera expressing the domain 4 sequence from 
PFO in place of the WT SLO sequence was generated to resolve the specificity of this 
region (SLO/PFOD4, Table 1).  Collection of the Triton X-100 insoluble membrane 
fractions demonstrated that the SLO/PFOD4 chimera protein localized to this fraction 
(Figure 5A).  However, extraction of membrane cholesterol using methyl-β-cyclodextrin 
(mβc) abolished the SLO/PFOD4 protein localization (Figure 5A) indicating that the 
chimera demonstrates the higher dependence on cholesterol characteristic of PFO.  In 
contrast, WT SLO was located in the Triton X-100 insoluble membrane fraction in the 
absence and presence of mβc, though decreasing the levels of cholesterol in the 
membrane does reduce SLO binding (Figure 5A).  Similar to the activity of PFO, the 
SLO/PFOD4 chimera protein in culture supernatants efficiently lysed rabbit erythrocytes 
in comparison to WT SLO (Figure 5B).  The ability of the SLO/PFOD4 expressing strain 
to conduct CMT was assessed through an infection of A549 cells.  Similar to the SLO- 
strain, the SLO/PFOD4 expressing strain is unable to translocate SPN (Figure 5B).  Thus, 
this suggests that cholesterol might not be directly involved in SPN translocation.  In 
addition, although the domain 4 sequence of WT SLO and PFO protein have a great 
degree of similarity, the PFO domain 4 was unable to replace the function of SLO 
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domain 4.  The sequence differences might prevent the SLO/PFOD4 chimera protein from 
binding to the membrane in an SLO specific manner. 
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Figure 5:  SLO/PFOD4 mutant is unable to conduct CMT.  (A) A549 cells in the absence or 
presence of methyl-β-cyclodextrin were infected for 3.75 hrs.  Afterwards, the cells were 
subjected to fractionation using Triton X-100.  A Western blot analysis is shown and is presented 
as described for Figure 1.  (B) The SLO/PFOD4 strain (Table 1) was tested for CMT efficiency 
(top) and hemolytic titers (bottom) and presented as described for Figure 1.  An ‘*’ indicates that 
CMT is significantly lower than WT (P<0.05).  N.D. denotes the limit of detection for hemolytic 
activity using an undiluted sample.  The data presented represent the mean and the standard 
deviation of the mean derived from at least three independent experiments. 
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A specific region of SLO Domain 4 is required for CMT:  Further inspection of the 
sequence differences between SLO and PFO domain 4 revealed that non-conserved 
amino acid changes occurred in clusters (Figure 2).  To ascertain if CMT activity would 
be restored to the SLO/PFOD4 expressing strain, several mutants were made by swapping 
PFO sequence with the corresponding SLO sequence in the areas with clusters of 
difference (SLO/PFOD4-swap1, SLO/PFOD4-swap2, and SLO/PFOD4-swap3, Table 1).  The 
clusters of variable sequence exist between the second and third cholesterol-binding loop 
and near the first cholesterol-binding loop (Figure 6).  Similar to WT SLO, the cluster 
swap mutant proteins SLO/PFOD4-swap1, SLO/PFOD4-swap2 and, SLO/PFOD4-swap3 were 
localized to the Triton X-100 insoluble membrane fraction in the absence and presence of 
mβc, although lowering the levels of cholesterol in the membrane does reduce protein 
binding (Figure 7A).  The cluster swap mutant proteins in culture supernatants also had 
hemolytic titers similar to that of WT SLO (Figure 7B).  The capability of the cluster 
swap expressing strains to translocate SPN was assessed after an infection of A549 cells.  
Similar to the SLO- and SLO/PFOD4 strains, the SLO/PFOD4-swap1 expressing strain 
translocated significantly less SPN than WT (Figure 7B; P<0.05).  In contrast, both the 
SLO/PFOD4-swap2 and SLO/PFOD4-swap3 strains regained the ability to translocate SPN at 
levels significantly higher than the SLO/PFOD4 strain (Figure 7B; P<0.05).  Hence, 
although domain 4 of SLO and PFO share a high degree of similarity, there are specific 
residues near the third cholesterol-binding loop that are necessary for CMT competency. 
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Figure 6:  Features of PFO domain 4: (A) A cartoon representation of the resolved PFO crystal 
structure is shown.  The protein secondary structures are represented as coils for α-helices and as 
arrows for β-sheets.  (B)  The domain 4 structure of PFO is magnified to illustrate specific 
portions of the protein.  The cholesterol binding loops are at the bottom of domain 4.  The yellow 
color represents the leucine residue located at the tip of the first cholesterol binding loop, the blue 
color represents the alanine residue located at the tip of the second cholesterol binding loop, and 
the red color represents the alanine residue located at the tip of the third cholesterol binding loop.   
Several mutations in domain 4 were made to assess the ability to restore CMT activity to the 
SLO/PFOD4 chimera.  The residues changed in the swap mutants are shown on the domain 4 
structure.  The SLO/PFOD4-swap1 residue changes are shown in orange, the SLO/PFOD4-swap2 
residue changes are shown in brown, and the SLO/PFOD4-swap3 residue changes are shown in cyan.  
All the images were generated using PyMOL and the domain 4 images are shown in the same 
orientation. 
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Figure 7:  Domain 4 of SLO provides the specificity to restore CMT to the SLO/PFOD4 
mutant.  (A) Untreated and methyl-β-cyclodextrin treated A549 cells were infected for 3.75 hrs 
and the cells were then subjected to Triton X-100 fractionation.  A Western blot analysis is shown 
and presented as described for Figure 1.  (B) The indicated strains (Table 1) were assessed for 
CMT efficiency (top) and hemolytic titers (bottom) and presented as described for Figure 1.  An 
‘*’ indicates that CMT is significantly lower than WT (P<0.05) and an ‘**’ indicates that CMT is 
significantly higher than the SLO/PFOD4 strain (P<0.05).  N.D. denotes the limit of detection for 
hemolytic activity using an undiluted sample.  The data presented represent the mean and the 
standard deviation of the mean derived from at least three independent experiments. 
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The domain 4 and N-terminal extension of SLO are unable to conduct CMT:  Previous 
reports show that the SLO N-terminal extension is required for CMT (23, 24).  The data 
in this report indicate that binding to the membrane is necessary; however, a specific 
primary structure allows SLO to bind the host cell membrane properly.  To assess if these 
two SLO structures can allow PFO to translocate SPN, the N-terminal extension of SLO 
was grafted onto the primary structure of PFO, which encodes domains 1, 2, and 3, 
followed by the SLO domain 4 sequence (SLONT;D4/PFO, Table1).  The SLONT;D4/PFO 
strain was assessed for CMT efficiency following a 3.75 hour A549 cell infection.  The 
WT strain was CMT-competent, in contrast SLONT;D4 was CMT deficient similar to the 
SLO- strain (Figure 8).  Thus although both structures are necessary for CMT, neither 
was sufficient to convert PFO into a CMT-competent protein. 
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Figure 8: The N-terminal extension and domain 4 of SLO are unable to make PFO CMT-
competent.  The indicated strains (Table 1) were tested for CMT efficiency.  An ‘*’ indicates that 
CMT is significantly lower than WT (P<0.05).  The data presented represent the mean and the 
standard deviation of the mean derived from at least three independent experiments. 
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Binding to cholesterol is not crucial for CMT:  The inability of the SLO/PFOD4 strain to 
translocate SPN calls into question the role of cholesterol during CMT.  To begin 
assessing the necessity for cholesterol in CMT, A549 cells treated with mβc were 
infected with WT S. pyogenes.  The levels of cholesterol removed during the treatment of 
mβc permit SLO to maintain membrane binding (Figure 5A) and do not affect CMT 
(Figure 9A).  Previous studies demonstrate that mutating a specific loop residue in SLO 
and other cytolysins disrupt cholesterol binding (6, 21).  Based on these studies, two 
strains expressing a mutation the first cholesterol-binding loop were generated (SLOL565G 
and SLOL565D, Table 1) to clarify if binding to cholesterol is necessary for CMT.  As 
expected, neither mutant was able to lyse rabbit erythrocytes due to the inability to bind 
to cholesterol.  The SLOL565G strain did translocate SPN at levels that were not 
statistically significant from WT the levels of CMT (Figure 9B).  The SLOL565D strain did 
translocate SPN at levels significantly higher than the SLO- strain (Figure 9B; P<0.05), 
although at levels slightly reduced from the WT strain.  In total, these data suggest that 
although cholesterol was not necessary it does enhance the efficiency of SPN 
translocation.   
140 
 
B
0
20
40
60
80
100
WT SLO
L565G
SLO-
8 N.D.Titer N.D. N.D.
SLO
L565D
A
0
20
40
60
80
100
WT WT
+ mβC
- mβC
*
 
 
Figure 9:  Cholesterol increases the efficiency of CMT.  (A) Untreated and methyl-β-
cyclodextrin treated A549 cells were infected for 3.75 hrs with the WT strain and tests for CMT 
efficiency as described for Figure 1.  (B) The indicated strains (Table 1) were assessed for CMT 
efficiency (top) and hemolytic titers (bottom) and presented as described for Figure 1.  An ‘*’ 
indicates that CMT is significantly higher than the SLO- (P<0.05).  N.D. denotes the limit of 
detection for hemolytic activity using an undiluted sample.  The data presented represent the 
mean and the standard deviation of the mean derived from at least three independent experiments. 
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DISCUSSION 
 
While there is a high degree of structural similarities between the CDCs, the 
differences in the primary sequence appear to be important in the ability of the cytolysin 
to function in CMT.  In this report, we demonstrate that without domain 4 SLO is unable 
to bind to the membrane and unable to conduct CMT.  However, binding to the 
membrane via domain 4 from ILY and PFO cannot restore CMT.  The inability of 
domain 4 from the related cytolysins to permit CMT suggests that SLO may bind to an 
alternative and currently unidentified host cell membrane receptor.  Thus, although 
binding is important for CMT there are specific interactions between domain 4 of SLO 
and the membrane that are not reproduced in the presence of domain 4 from other 
cytolysins. 
Expressing domain 4 from ILY in place of the native SLO sequence was not 
adequate for CMT.  The domain 4 residues of ILY are too divergent to substitute for 
SLO.  However, a previous report suggests that changing the three variant residues of the 
ILY undecapeptide is enough to alter the target cell specificity of the cytolysin making it 
similar to SLO (26).  Generating the same changes as reported (26) in the sequence of the 
variant ILY undecapeptide, in the context of the SLO/ILY domain 4 chimera, could not 
restore CMT.  Thus even though changing the undecapeptide sequence may change the 
specificity of ILY these changes are not enough to overcome the inability of the 
SLO/ILY domain 4 protein to make the proper contacts with the membrane. 
In contrast to ILY, SLO and PFO share a large degree of primary structure 
similarity in the 110 amino acid region of domain 4 and there are 28 non-conserved 
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changes between the two proteins in this domain.  Yet these changes were enough to 
prevent the SLO/PFO domain 4 chimera from making the appropriate contacts with the 
membrane.  The majority of the differences exist between the second and third 
cholesterol-binding loop, with a small group of residue changes near the first cholesterol-
binding loop.  Replacing the PFO residues near the first cholesterol-binding loop with 
residues from SLO, in the context of the SLO/PFO domain 4 chimera (SLO/PFOD4-swap1), 
did not reestablish WT SLO levels of CMT.  The SLO/PFOD4-swap1 protein could bind to 
the membrane but the strain expressing the protein could not conduct CMT.  However, 
another domain 4 swap protein, which had four residue changes close to the first 
cholesterol-binding loop, eliminates both membrane binding by the protein and SPN 
translocation by the strain, similar to the SLOΔD4 strain (data not shown).  Hence, 
replacement of the residues near the first cholesterol-binding loop in the SLO/PFO 
domain 4 chimera cannot reinstate CMT.  On the other hand, replacing the residues 
between the second and third cholesterol-binding loop significantly increases the ability 
of the SLO/PFOD4-swap2 and SLO/PFOD4-swap3 to carry out CMT.  This area has the highest 
number of non-conserved residue changes between SLO and PFO in domain 4.  The 
capacity of the strains, which express these protein mutants, to conduct CMT indicates 
that the residues close to the third cholesterol-binding loop in SLO domain 4 are likely 
required for binding to an unknown membrane receptor.  
Cholesterol must be present in the membrane for domain 4 of PFO to bind (7, 16).  
Treating cells with mβc diminishes the ability of SLO/PFO domain 4 protein to bind to 
the membrane indicating it has the cholesterol binding characteristics of PFO.  The 
inability of the SLO/PFO domain 4 strain to translocate SPN also suggests that SLO and 
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PFO bind to the membrane in a dissimilar manner.  An earlier report demonstrates that 
SLO, unlike PFO, can bind to membranes with reduced amounts of cholesterol (10). In 
addition, the SLO requirement for cholesterol pertains to its ability to form pores in the 
membrane and requires the presence of the cholesterol binding loops (6, 10).  The ability 
of WT S. pyogenes to conduct CMT in the presence of mβc indicates that decreasing the 
levels of cholesterol in the membrane does not affect the process.  Furthermore, unlike 
the SLO/PFO domain 4 strain mutating the main cholesterol-binding loop of SLO does 
not abolish CMT.  A earlier report indicates that mutating the main cholesterol binding 
loop of cytolysins produces a protein that cannot assemble oligomers and is locked in the 
monomer state (34). Hence, the reduced ability of the SLOL565D strain to translocate SPN 
suggests that it is similar to a monomer-locked mutant (23).  This indicates that similar to 
oligomerization, cholesterol enhances CMT.  
While the SLO N-terminal extension and D4 primary structures are necessary for 
CMT, they are not sufficient to make PFO a CMT-competent translocator.  Thus, while 
these two structures may make contact with an unknown receptor, the remaining primary 
sequence of SLO might bind to SPN.  Alternatively, the N-terminal extension might 
adopt a specific conformation when it is contact with either domain 1, 2, or 3 of SLO. 
Overall, the data suggests that in addition to cholesterol, SLO binds to an 
unknown receptor in the host cell membrane likely using the region near the third 
cholesterol-binding loop.  Furthermore, contacts with cholesterol in the membrane 
enhance CMT by allowing oligomerization to occur.  
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MATERIAL AND METHODS 
 
Table 2.  Primers used in this study. 
Name Sequence/Description a 
NM091p 
NM092p 
TACGCGAATGTTTCTAACATTTCCCTTGAAACGGAGAGT 
AAAGTACTAGAGTGCACCGGCTTAGCTTGGGAATGGTGGCGACTG  
Inverse PCR mutagenesis primers for SLO/ILYD4-ECW mutant 
NM133p 
NM134p 
NM135p 
NM136p 
AAAAAACTCGAG
CTTTGTCGTCATAATTGATTTCATCCCAAAGGATTTC 
GCCTATGGTCGAACTGTTTTTGTCAAAC 
CAATTATGACGACAAAGGAAAAGAAGTTATTACTAAAC 
AAAAAAATCGAT
Sequence overlap extension mutagenesis primers used for SLO/PFOD4-swap1 
AGCTGGTTATTCTATAAGACAAAACAC 
NM123p 
NM124p 
ATCTCTTTCGTCTATAACTTTTCTCCACCATTCCCA 
GTTAAATTATCTAAAGAAATAAATGTTTCAATATGG 
Inverse PCR mutagenesis primers for SLO/PFOD4-swap2 
NM125p 
NM126p 
TTTATCATAATAATTTCCATCCCAACGTTTATG 
ACAGCTCCATATTCAACAGTAATACCTCTTGGAGCTAATGCA 
Inverse PCR mutagenesis primers for SLO/PFOD4-swap3 
NM111p 
NM1112p 
ACCATATGGGCTGTCGGTTGATCCTGAGAT 
TCGATTACTTATAAGTAGGACTGGTTCAAG 
Inverse PCR mutagenesis primers for SLOL565D 
NM113p 
NM114p 
ACCATATGGGCTCCCGGTTGATCCTGAGAT 
TTGAGCAACATAGTCGCCTTGATGAGACAGGTT 
Inverse PCR mutagenesis primers for SLOL565G 
a Allelic replacement was used to substitute the endogenous allele in WT JRS4 with the 
mutant alleles
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Bacterial Strains:  Molecular cloning experiments utilized Escherichia coli TOP10 
cultured in Luria-Bertani broth at 37°C.  S. pyogenes utilized were of M serotype 6 strain 
JRS4.  Routine culture of S. pyogenes occurred at 37°C in Bacto™ Todd-Hewitt broth 
(ThyB) supplemented with 0.2% BBL™ autolysed yeast extract.  At appropriate times, 
erythromycin was added to media to final concentrations of 750 μg/ml for E. coli and 1 
μg/ml for S. pyogenes. 
 
Manipulation and computational analyses of DNA:  Transformation of E. coli used the 
method of Kushner (Kushner 1978) and plasmid DNA was isolated from E. coli using 
standard techniques.  S. pyogenes was transformed by electroporation as previously 
described (4). Restriction endonucleases, ligases, and polymerases were used according 
to manufacturer’s recommendations.  The fidelity of all DNA sequences created by 
polymerase chain reaction (PCR) was validated by DNA sequencing analyses performed 
by a commercial vendor (Genewiz; South Plainfield, NJ, USA). 
 
Construction of SLO domain 4 mutants:  A custom gene synthesis approach was used 
to generate the nucleotide coding sequence of the SLO/PFOD4, SLO/ILYD4, and 
SLONT;D4/PFO mutants in the pUC57 vector (Genscript; Piscataway, NJ, USA).  The 
nucleotide sequences were then removed from pUC57 and inserted into the pJRS233, 
suicide shuttle vector containing an erythromycin resistance cassette, using the restriction 
endonuclease enzymes XhoI and ClaI.  An inverse PCR method was used to generate the 
SLO/ILYD4-ECW mutant from the SLO/ILYD4 nucleotide sequence present in pJRS233, 
using the primers NM091p and NM092p.  Sequence overlap extension mutagenesis (PCR 
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SOEing, (17)) was used to make the SLO/PFOD4-swap1 mutant from the SLO/PFOD4 
nucleotide sequence present in pJRS233. The primer pair NM133 and NM134p and the 
primer pair NM135p and NM136p were used to generate two PCR products.  The two 
~0.5 kb PCR products were purified and both were added to a subsequence amplification 
reaction, which used the primers NM133p and NM136p.  The product of the second 
round PCR was cleaved with XhoI and ClaI and inserted into pJRS233.  The inverse PCR 
method was used to generate the SLO/PFOD4-swap2 and SLO/PFOD4-swap3 mutants from the 
SLO/PFOD4 nucleotide sequence present in pJRS233, using the primers NM123p and 
NM124p and the primers NM125p and NM126p, respectively.  The cholesterol-binding 
mutants, SLOL565D and SLOL565G, were made using the inverse PCR method from the WT 
slo nucleotide sequence present in pJRS233, using the primer set NM111p and 112 and 
the primer set NM113p and 114p, respectively.  The JRS4 WT slo allele was replaced 
with the mutants as previously described (19). All primer sequences are listed in Table 2 
with restriction endonuclease site underlined. 
 
Analysis of hemolytic activity:  Cell free overnight S. pyogenes culture supernatants 
were used to measure the ability of various SLO mutants to lyse rabbit defibrinated 
erythrocytes (22). Where noted, human erythrocytes were collected from a volunteer and 
used to assess hemolytic activity.  Hemolytic titer is defined as the reciprocal of the 
dilution that produced 50% lysis (22, 24).  The limit of detection for hemolysis is 
specified by a designation of not detected (N.D.), which meant that lysis did not occur in 
the presence of undiluted supernatant. 
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Analysis of CMT:   Analysis of CMT was conducted as previously described (9, 24).  
Briefly, A549 cells (ATCC CCL-185) were grown in 75 cm2 tissue culture flasks in the 
presence of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 50 mM 
HEPES, 8 mM L-glutamine, and 10% fetal bovine serum.  The confluent cells were 
infected with various streptococcal strains as mentioned in the text.  To prepare for the 
infection, streptococcal cultures were grown overnight in ThyB, subjected to 
centrifugation, washed twice with phosphate saline buffer (PBS), and resuspend in pre-
warmed medium to an OD600 of 0.66.  The A549 cells were incubated with 1 mL of the 
resuspended streptococcal strains plus 14 mL of fresh medium for 3.75 hrs at 37°C in the 
presence of 5% CO2.  After the infection, the culture supernatant was collected and filter 
sterilized.  The A549 cells were washed twice with PBS, lysed with a 0.05% saponin-
protease inhibitor mixture, and the cytosolic fractions prepared as previously described 
(22, 24).  The SPN activity in the A549 cytosolic fraction was analyzed by measuring 
cleavage of β-NAD+ as described earlier (22, 24).  Where indicated, methyl-β-
cyclodextrin (cat.#C4555, Sigma) was added to media for 60 minutes prior to infection 
by streptococcal strains. 
 
Statistical Analysis:  Any differences in the mean values of CMT translocation  
efficiencies compared between various mutant and WT strains were tested for 
significance by the unpaired t-test (13) and P-values less than 0.05 were considered 
significant. 
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A549 cell membrane extraction:  Cell membranes were prepared and analyzed as 
previously described (22).  In brief, after 3.75 hr infection, the medium was removed 
from the A549 cells and the cells were washed twice with ice-cold Tris-buffered saline 
(pH 7.5).  The cells were lysed in TBS containing 1% Triton X-100 (Sigma), scraped 
from the flask, transferred to a tube, and incubated at 4°C for 30 min.  The suspension 
was then subjected to centrifugation (19900 x g, 15 min, 4°C) and the soluble material 
was transferred to a new tube and the insoluble material was resuspended in SDS sample 
buffer (100 mM Tris-HCl [pH 6.8]; 20 mM DTT; 4% SDS [weight/vol]; 20% glycerol 
[vol/vol]; and 0.2% bromophenol blue [weight/vol]).  The soluble material was diluted 
1:4 in SDS sample buffer.  The soluble and insoluble fractions were then analyzed by a 
Western blot using anti-SLO antiserum.  Where indicated, methyl-β-cyclodextrin 
(cat.#C4555, Sigma) was added to media for 60 minutes prior to infection by 
streptococcal strains. 
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CONCLUSIONS 
 
Cytolysin-mediated translocation appears to be a specific process that uses 
streptolysin O (SLO) to transport the S. pyogenes NAD+- glycohydrolase (SPN) into host 
cells.  Since SLO is a member of the cholesterol-dependent cytolysin family of proteins, 
there was a proposal that CMT might be a general mechanism used by the cytolysins to 
translocate effector proteins.  However, during the course of this work accounts 
describing a similar mechanism in other species of Gram-positive bacteria have not been 
published.  Prior to and while the studies in this report were occurring, several papers 
were published revealing the following details: CMT has a role in virulence, CMT cannot 
occur when a related cytolysin is expressed in lieu of SLO, SLO can differentiate 
between secreted S. pyogenes substrates, SPN is a strict NAD+-glycohydrolase, and 
expression of SPN requires the presence of an endogenous inhibitor that protects against 
the NAD+-glycohydrolase activity (1, 2, 4, 5, 7, 8, 10, 11).   
The major aspects of CMT described in these reports were that 1) CMT can occur 
in the absence of SLO pore formation, 2) cytotoxicity requires both SLO pore formation 
and SPN translocation, 3) binding to the host cell membrane is necessary, but general 
binding to the membrane is insufficient for CMT, 4) a specific region of SLO domain 4 is 
important for CMT, 5) reducing the levels of cholesterol in the membrane with an 
inhibitor does not affect CMT, and 6) a chimera expressing the SLO N-terminal 
extension and SLO domain 4 with the primary structure of PFO does not produce a 
CMT-competent protein. Although these results are salient, they do not provide a distinct 
mechanism for how SLO translocates SPN into the host cell cytosol. 
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The original CMT model proposes that SPN enters the host cell through the 
lumen of the SLO pore; however, prior data suggests the method of translocation is more 
complicated (5, 10).  To further characterize the mechanism of CMT, the experiments 
described in this thesis were conducted.  In Chapter 2, the purpose of the experiments 
was to answer the following questions: 1) Is pore formation by SLO required for SPN 
translocation?  2) Is SLO oligomerization necessary for CMT?  3) Does cytotoxicity 
require SLO pore formation?  The data from these experiments and others were presented 
in this chapter and published to advance the knowledge pertaining to CMT (9).  A strain 
expressing a prepore-locked SLO protein was capable of SPN translocation even though 
the protein was unable to form pores in A549 cells and rabbit erythrocytes.  This 
indicated that SLO pore formation was not necessary for CMT.  Additionally, a strain 
expressing a monomer-locked SLO protein could also translocate SPN but not as 
effectively as the prepore-locked strain.  Thus, this data supports the concept that pore 
formation is not required and demonstrated that SLO oligomerization enhances CMT.  
Although the prepore-locked strain translocates SPN, this strain is non-cytotoxic.  A co-
infection with prepore-locked and SPN- strains partially restored the levels of 
cytotoxicity, suggesting that the toxic effects were most efficient when SPN translocation 
and SLO pore formation were coupled.  In total, these results demonstrated that the two 
activities of SLO, pore formation and SPN translocation, could be uncoupled but that 
pairing of these activities augments S. pyogenes cytotoxicity. 
Although the results from Chapter 2 dramatically shift the CMT paradigm, the 
data did not provide a lucid mechanism for translocation.  We began a series of 
experiments in Chapter 3 to assess the role of host cell endocytosis in CMT and to detect 
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an interaction between SPN and SLO.  In particular, we were interested in using 
inhibitors identified as being effective against various proteins involved in host cell 
endocytosis.  We revealed that an inhibitor of PI3-kinase, LY294002, does not affect 
SPN translocation.  In conjunction with data presented in Chapter 2, which showed an 
inhibitor of actin polymerization does not affect CMT, this strongly suggests that 
clathrin-dependent endocytosis is not involved in the translocation of SPN.  There are 
several recognized pathways for clathrin-independent endocytosis in host cells such as 
caveolae-mediated endocytosis (3).  Many of these pathways begin in specific cell 
membrane domains and use various kinases to signal into the host cell.  Cholesterol-
enriched domains of the membrane are sites of potential endocytosis and using nystatin, a 
compound that sequesters the sterol, we showed that there was no decrease in the levels 
of SPN translocation.  Preliminary data also suggests that CMT is unaffected by 
inhibition of protein kinase C, an indication that caveolae-mediated endocytosis might 
not be involved.  Although, we did not determine if an alternate host cell endocytosis 
pathway is involved in CMT, we examined the ability of SLO and SPN to interact in a 
bacterial two-hybrid system.  We did not detect an interaction between SPN and SLO in 
this system; however, we did detect binding between SPN and the immunity factor for 
SPN.  The data presented in Chapter 2 illustrated that the monomer-locked SLO strain 
could translocate SPN suggesting that these two proteins could interact as individual 
polypeptides.  Hence, SPN might only bind to SLO in the presence of an unknown 
accessory protein present in the host cell membrane.  Attempts to detect an interaction 
between the putative protein SpyM3-0131 and SLO or SPN were unsuccessful.  In total, 
the results from Chapter 3 suggest a clathrin- and caveolae-independent endocytosis 
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pathway of the host cell might participate in CMT and that an accessory protein may be 
necessary to allow SPN and SLO to bind.   
To support our mission of defining a mechanism for CMT, we initiated studies to 
determine if there was specificity involved in the binding of SLO domain 4 to the host 
cell membrane.  The goal of the experiments in Chapter 3 was to address the following 
set of questions: 1) Is binding to the membrane necessary for CMT?  2) Can the domain 4 
primary structure of a related cytolysin functionally replace domain 4 of SLO and allow 
the protein chimera to perform CMT?  3) Is the presence of cholesterol required during 
SPN translocation?  The results from experiments pertaining to these questions were 
presented in this chapter and will be submitted for publication.  Deletion of SLO domain 
4 prevented SPN translocation, an indication that membrane binding is necessary.  
However, replacing the native SLO domain 4 amino acid sequence with that of ILY, 
which binds to the membrane protein CD59, or with PFO, which binds to cholesterol, did 
not restore CMT suggesting that binding to the host cell membrane is not sufficient.  
Since SLO and PFO share a high degree of similarity in the domain 4 region, we made 
three strains in which portions of the PFO domain 4 sequence were replaced with SLO 
sequence in the background of the SLO/PFOD4 chimera.  After restoring the native SLO 
sequence to an area of domain 4 that has the highest number of non-conversed amino 
acid differences between the two cytolysins, two of the strains expressing the sequence 
swaps in the SLO/PFOD4 chimera regained the ability to translocate SPN.  This result 
suggests that this specific region, closest to the third cholesterol-binding loop, of SLO 
domain 4 makes important contacts with the host cell membrane.  Given that the 
SLO/PFOD4 strain failed to translocate SPN, the requirement for cholesterol in CMT was 
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in question.  We demonstrated that treatment of host cells with methyl-β-cyclodextrin 
(mβc) sufficiently reduced the levels of cholesterol in the membrane and eliminated the 
SLO/PFOD4 chimera localization to membrane fractions; however, wild type (WT) SLO 
continued to localize to membrane fractions after identical mβc treatments.  These results 
suggest that SLO domain 4 has a higher tolerance for diminished membrane cholesterol 
than PFO domain 4.  Furthermore, we discovered that treatment of host cells with mβc 
did not alter the SPN translocation capability of WT S. pyogenes.  To further probe the 
role of cholesterol, we generated S. pyogenes strains that expressed a point mutation in 
the main domain 4 loop responsible for the ability of cytolysins to bind to cholesterol.  
We observed that the CMT levels of the SLOL565G strain are not statistically significant 
from those of WT.  In addition, the SLOL565D strain also could translocate SPN, however, 
the levels were slightly lower than WT.  A previous report indicates that point mutations 
in the main cholesterol-binding loop create cytolysins that are locked in the monomer 
state (12).  Thus, these studies suggest that although cholesterol is not required it does 
enhance CMT.  
In summary, the experiments detailed in this thesis demonstrate the intricacy of 
CMT.  This process begins with adherence of S. pyogenes to the surface of host cells, 
followed by the expression and secretion of SLO and SPN near the host cell membrane.  
SLO binds to the host cell membrane via domain 4, in which a specific region near the 
third cholesterol-binding loop is necessary.  After binding, SLO forms oligomers and in 
the absence of a pore translocates SPN into the host cell cytosol.   
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FUTURE DIRECTIONS  
 
To gain a complete comprehension of the specific mechanism of CMT and the 
role of this secretion system in S. pyogenes pathogenesis, numerous experiments must be 
completed.  The major question that remained unresolved at the end of my research in 
Chapter 2 is the following, how does SLO translocate SPN in the absence of a pore?  The 
experiments we began in Chapter 3 to address this question provided some useful details.  
To examine this question using the various inhibitors of host cell endocytosis, attempts to 
use reduced concentrations of the compounds must occur to decrease the potentially toxic 
affect on S. pyogenes SPN secretion.  If these attempts are unsuccessful, cell lines 
expressing mutations in proteins involved in host cell endocytosis can help determine the 
effect on CMT.  Alternatively, RNA interference can target transcripts in cell lines to 
decrease the levels of protein expression and ascertain if there is an effect on CMT.  
Experiments in which A549 cells express the dominant negative mutant dynaminK44A will 
help assess how the activity of this GTPase affects CMT.  Dominant negative mutants of 
Arf1 and Arf6 could also provide insights into the role of vesicle trafficking in CMT.  
Expression of short interfering RNA (siRNA) constructs that would decrease the 
expression of caveolin-1 could help to determine whether caveolae-mediated endocytosis 
plays a role in CMT.  Other siRNA constructs that would possibly yield information 
about the involvement of host cell endocytosis in CMT are tyrosine kinase (i.e. Src, Fyn) 
and small GTPase (i.e. cdc42, rhoA, rac) targets.  These initial experiments should aid in 
elucidating the role of the host cell in CMT.  Other prospective experiments include 
isolating endosomes at various time points from infected cells to determine the type of 
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vesicle SLO and SPN may inhabit by identifying known markers or tagging SLO and 
SPN with different fluorophores with the goal of using microscopy to follow CMT. 
The necessity for additional S. pyogenes secreted proteins in CMT is 
undetermined.  To assess this possibility, the entire CMT operon (spn, ifs, slo) could be 
expressed heterologously from a plasmid in Lactococcus lactis.  Such a construct with the 
sequence of the entire operon currently exists in the shuttle vector pABG5.  Since L. 
lactis does not normally adhere to host cells, an S. pyogenes adhesion, such as M protein, 
would also need to be expressed in the bacteria.  Alternatively, purified SLO and SPN 
can be used to reconstitute CMT.  However, the success of this procedure will require 
precise determination of the concentrations of each protein.  To prevent complete lysis of 
the cells by WT SLO, the prepore-locked SLO could be used in these studies.  The ability 
to recreate the system in the absence of S. pyogenes would suggest that no other bacterial 
factors are necessary and that once SLO and SPN are in close proximity to the host cell 
membrane translocation can occur.  In my opinion, the ability to reconstitute CMT with 
purified proteins in the absence of S. pyogenes would be useful since future research 
could occur without concern regarding bacterial adherence or variable protein secretion.  
However, based on previous data it may not be possible to use a purified protein system 
for CMT if the localized concentrations of SPN and SLO near the host cell membrane are 
not optimal (8).  The process of CMT appears to be extremely coordinated and attempts 
to develop of protein-based system may not succeed.  In Chapter 3, mutating the SpeB 
cleavage site in the N-terminal extension of SLO abrogates CMT.  This suggests that 
processing of this site occurs before SPN translocation.  Other S. pyogenes strains that 
could help elucidate the role of this site in CMT include a mutant expressing an in-frame 
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deletion in speB, a point mutation in the active site of  speB (C192S), and additional 
truncations of the slo N-terminal extension (i.e. SpeB cleaved version of slo).  The SpeB 
cleavage site mutant may have an improperly folded SLO N-terminal extension, which 
could be the basis for the decrease in CMT.  It is also possible that a host cell protease 
(i.e. furin), and not SpeB, cleaves this site before CMT can occur.  An infection of host 
cells in the presence of a cysteine protease inhibitor, E64, would help assess this 
possibility.  However, in the Triton X-100 studies conducted during this thesis there was 
not any evidence of a cleaved form of SLO in the membrane fractions following an 
infection with S. pyogenes.  Thus in my opinion, the inability of the SpeB cleavage site 
mutant to translocate SPN is likely a result of misfolding and any additional changes to 
the SLO N-terminal extension will likely halt the ability of SLO to translocate SPN. 
Although the N-terminal extension is necessary, its role in CMT continues to be 
ambiguous.  The bacterial two-hybrid system in Chapter 3 did not detect an interaction 
between SPN and the SLO N-terminal extension.  It is possible that this SLO primary 
structure is binding to a component of the host cell membrane to increase the efficiency 
of CMT.  Within the 66 amino acid sequence, there are a number of charged and polar 
residues, including a cluster of six charged residues that occur near the end of the 
sequence.  The absence of hydrophobic residue clusters in the N-terminal extension 
suggests that it is probably unstructured until it binds to an unknown molecule.  To 
continue probing the significance of this region, mutational analysis could test the 
importance of each of the N-terminal extension charged residues.  Those mutants that 
alter the ability of SLO to perform CMT should also be tested for defects in membrane 
binding.  Future experiments could use the data obtained from the N-terminal extension 
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studies to construct fluorescently labeled peptides, to be used in enzyme-linked 
immunosorbent assays or fluorescence polarization assay to measure binding to purified 
host membrane proteins and host membrane lipids in liposomes.   
Towards the end of Chapter 4, the ability of the SLO N-terminal extension and 
the domain 4 primary structure to convert perfringolysin O (PFO) into a CMT-competent 
protein failed.  Both of these components of SLO are known to be necessary but not 
sufficient for CMT.  In this chimera protein, domain 4 of SLO is likely making the proper 
contacts with the host cell membrane.  It is possible that once SLO binds to the host 
membrane the conformation changes in the remainder of the molecule repositions the N-
terminal extension and prepares it for binding to either SPN or a co-receptor in the host 
membrane.  SLO and PFO are 67%  identical and 83% similar across all four domains of 
the proteins (6).  However, based on our domain 4 studies this high level of similarity is 
not sufficient for PFO to translocate SPN.  Thus, the primary structure differences 
between SLO and PFO are sufficient to hinder the capability of most SLO/PFO chimera 
proteins to conduct CMT.  Mutagenesis studies could be used to replace PFO sequence 
with SLO sequence in this chimera.  The areas with the largest number of amino acid 
difference between SLO and PFO should be targeted for replacement in the chimera 
protein.  Overall, based on this data, future SLO mutagenesis studies should possibility 
only change a few residues at a time to assess accurately the effects the mutations on the 
translocation of SPN.   
As of yet, we have been unable to detect an interaction between SPN and SLO.  It 
is possible that SLO must bind to its receptor before binding to SPN.  In Chapter 4, we 
identified a specific primary structure in SLO domain 4, near the third cholesterol-
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binding loop, that can restore CMT suggesting this region of SLO is important for host 
cell membrane binding.  Although SLO can bind to cholesterol, there is likely a co-
receptor involved in the binding of the cytolysin.  To begin the process of identifying the 
potential receptor, purified His-tagged WT and prepore-locked SLO can be immobilized 
on a column filled with cobalt chelate resin and isolated host cell membrane fractions 
poured into the column.  Any proteins isolated with SLO and visible on a stained SDS-
polyacrylamide gel can be identified by sequencing.  The pBAD-geneIIIb expression 
plasmids containing the sequence of WT and prepore-locked slo already exist and have 
been used to produce purified proteins (9).  Alternatively, purified His-tagged prepore-
locked SLO can be added to cells, followed by treatment with a cross-linker, and 
identification of potential receptors.  To assess if a glycolipid or glycoprotein might be 
involved, host cells can be enzymatically treated with various endoglycosidase to assess 
the effect on CMT, however, there is a possibility that this would affect S. pyogenes 
adherence.  Another method to identify a potential lipid receptor is the protein lipid 
overlay technique, in which serial dilutions of various lipids are blotted onto 
nitrocellulose membrane, followed by incubation with purified protein, and detection 
using an immunoblot.  It is possible the SPN also binds to an unknown membrane 
molecule.  To assess this option, analysis of purified SPN in the assays listed above can 
occur concurrently with SLO.  In my opinion, the future studies of CMT should focus on 
identification of the SLO receptor.  This would permit more in depth studies on the 
mechanism of translocation to continue. 
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